- Conditions: Type 1 Diabetes; Type 2 Diabetes
Intervention:
Sponsors: Metabolic Fitness Association, Italy; Metabolic Fitness Association, Italy; University of Roma La Sapienza
Recruiting - verified May 2012 - Condition: Spinal Deformity
Intervention: Device: Tantalum cage from Zimmer
Sponsors: Rigshospitalet, Denmark; Rigshospitalet, Denmark
Recruiting - verified May 2012 - Condition: Anomaly of Dental Arch
Interventions: Device: Removable partial denture (Chrome Cobalt Distal); Other: A classic SDA
Sponsors: University of the Western Cape; University of the Western Cape
Not yet recruiting - verified May 2012 - Conditions: HIV Infection; Tuberculosis
Interventions: Drug: Lopinavir/Ritonavir; Drug: Lopinavir/Ritonavir; Drug: Raltegravir; Drug: Isoniazid; Drug: Pyridoxine; Drug: Pyrazinamide; Drug: Ethambutol; Drug: Rifabutin; Drug: Rifampin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Heterotaxy Syndrome
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified May 2012 - Conditions: Metatarsus Adductus; Metatarsus Varus
Interventions: Device: UNFO-s; Procedure: cast
Sponsors: Unfo Ltd.; Unfo Ltd.
Not yet recruiting - verified May 2012 - Condition: Shock, Septic
Interventions: Other: blood sampling; Other: blood sampling
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne
Not yet recruiting - verified May 2012 - Condition: Chest Pain
Interventions: Drug: Marinol; Drug: Placebo
Sponsors: University of Iowa; University of Iowa
Recruiting - verified May 2012 - Condition: Hepatitis C Virus
Interventions: Biological: Peginterferon Lambda-1a; Biological: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Telaprevir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Placebo; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550; Drug: BI 1015550
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma; Chronic Myelogenous Leukemia
Intervention: Biological: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Entecavir + Tenofovir (MDR group)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital
Not yet recruiting - verified May 2012 - Conditions: Schizophrenia; Schizophreniform Disorder; Brief Psychotic Disorder; Substance Induced Psychosis
Interventions: Drug: Melatonin; Drug: Placebo
Sponsors: Guilan University of Medical Sciences; Guilan University of Medical Sciences
Recruiting - verified May 2012 - Condition: Pulmonary Hypertension
Interventions: Drug: iloprost nebuliser solution; Drug: distilled water
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine; Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery
Not yet recruiting - verified May 2012 - Condition: Infertility
Intervention: Procedure: Embryo selection based on polscope grading or morphology
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Other: Neuroimaging & Neuropsychological Evaluation; Other: Neuroimaging & Neuropsychological Evaluation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University
Recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cytomegalovirus Infection; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Isolated Plasmacytoma of Bone; Monoclonal Gammopathy of Undetermined Significance; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Multiple Myeloma; Stage I Small Lymphocytic Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IIIA Mycosis Fungoides/Sezary Syndrome; Stage IIIB Mycosis Fungoides/Sezary Syndrome; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Small Lymphocytic Lymphoma; Stage IVA Mycosis Fungoides/Sezary Syndrome; Stage IVB Mycosis Fungoides/Sezary Syndrome; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Biological: tetanus-CMV fusion peptide vaccine; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention: Drug: FTY720
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Conditions: End Stage Renal Disease; Venous Stenosis
Intervention: Drug: Sirolimus
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Pfizer
Recruiting - verified May 2012 - Condition: Inflammatory Bowel Diseases
Intervention: Other: Salivary samples
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified April 2012 - Condition: Congenital Anomaly of Pregnant Women
Intervention:
Sponsors: Hillel Yaffe Medical Center; Hillel Yaffe Medical Center; Technion, Israel Institute of Technology
Not yet recruiting - verified April 2012 - Conditions: Traumatic Brain Injury; Coagulation Disorder
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified May 2012 - Condition: Neoplasm Malignant
Interventions: Drug: SAR245408; Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified April 2012 - Condition: Respiratory Distress Syndrome
Interventions: Device: Neurally Adjusted Ventilatory Assist (NAVA); Device: SiPAP - placebo
Sponsors: Fraser Health; Fraser Health
Not yet recruiting - verified April 2012 - Condition: Adenovirus
Intervention:
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; Department of Defense
Recruiting - verified April 2012 - Condition: Shoulder Dislocation
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Pulmonary Hypertension
Interventions: Drug: Carvedilol; Drug: Carvedilol placebo
Sponsors: The Cleveland Clinic; The Cleveland Clinic; National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: BI 411034; Drug: BI 411034; Drug: BI 411034; Drug: BI 411034; Drug: BI 411034; Drug: BI 411034; Drug: BI 411034; Drug: BI 411034; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Vitamin B12 Deficiency
Interventions: Dietary Supplement: L-5-methyltetrahydrofolate (Metafolin ®); Dietary Supplement: folic acid; Dietary Supplement: Placebo
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV); Drug: Daclatasvir (DCV); Drug: PBO matching ASV; Drug: Placebo (PBO) matching DCV; Drug: Pegylated-interferon alfa 2a (PegIFN); Drug: Ribavirin (RBV)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Conditions: Congenital Heart Disease; Disorder of Fetus or Newborn
Interventions: Drug: Methylprednisolone; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Conditions: Radiation Pneumonitis; Locally Advanced Lung Cancer
Intervention:
Sponsors: Instituto Nacional de Cancerologia de Mexico; Instituto Nacional de Cancerologia de Mexico; National Council of Science and Technology, Mexico
Not yet recruiting - verified April 2012 - Condition: Hypoplastic Left Heart Syndrome
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Pediatric Heart Network
Not yet recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Drug: BI 655066 (high medium i.v. dose); Drug: BI 655066 (very low i.v. dose); Drug: BI 655066 (low i.v. dose); Drug: BI 655066 (low medium i.v. dose); Drug: BI 655066 (low s.c. dose); Drug: BI 655066 (high i.v. dose); Drug: BI 655066 (very high i.v. dose); Drug: Placebo, i.v.; Drug: BI 655066 (high s.c. dose); Drug: Placebo, s.c.
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Genetic: gene expression analysis; Other: flow cytometry; Other: fluorescence activated cell sorting; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Dilated Cardiomyopathy
Interventions: Drug: perindopril; Drug: placebo
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2012 - Condition: Congenital Heart Disease
Intervention: Drug: Sildenafil
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Not yet recruiting - verified March 2012 - Conditions: Chromosome 13 Aneuploidy; Chromosome 18 Aneuploidy; Chromosome 21 Aneuploidy; Sex Chromosome Aberrations; Other Microdeletions
Interventions: Procedure: Blood draw; Procedure: Cheek swab/Saliva Sampling
Sponsors: Natera, Inc.; Natera, Inc.
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Interventions: Drug: SC-PEG; Drug: Oncaspar
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Sigma Tau; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005; Drug: FOLFIRI
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Pancreatic Masses
Interventions: Procedure: EUS-FNA; Device: EUS-FNA with suction; Device: EUS-FNA without suction
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified April 2012 - Conditions: Intestinal Failure; Short Bowel Syndrome
Interventions: Drug: Glucagon-Like Peptide 2; Drug: Glucagon like peptide-2
Sponsors: Alberta Children's Hospital; Alberta Children's Hospital; Stollery Children's Hospital; The Hospital for Sick Children; Children's & Women's Health Centre of British Columbia
Recruiting - verified April 2012 - Conditions: Klinefelter Syndrome; XXY Syndrome
Interventions: Drug: Testosterone gel 1%; Drug: Placebo gel
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Colorado Clinical & Translational Sciences Institute; Children's Hospital Colorado; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012 - Condition: Mild Cognitive Impairment
Intervention:
Sponsors: Pamlab, L.L.C.; Pamlab, L.L.C.; Clionsky Neuro Systems, Inc.
Recruiting - verified May 2012 - Conditions: Sickle Cell Disease; Respiration Disorders
Intervention: Drug: Hydroxycarbamide
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified March 2012 - Conditions: Healthy; Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions: Drug: dacomitinib; Drug: dacomitinib; Drug: dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: tosedostat; Drug: cytarabine; Drug: decitabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Schizophrenia
Interventions: Drug: Moxonidine; Drug: Placebo; Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute; Alfred and Baker Medical Unit - Alfred Hospital; Monash Medical Centre - Southern Health; Ballarat Health Service Psychiatric Services
Not yet recruiting - verified April 2012 - Conditions: Connective Tissue; Musculoskeletal Pain
Intervention:
Sponsors: Stromatec, Inc.; Stromatec, Inc.; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified April 2012 - Condition: Neurovascular Diseases
Intervention:
Sponsors: Rennes University Hospital; Rennes University Hospital
Not yet recruiting - verified March 2012 - Condition: Barrett's Esophagus
Interventions: Drug: Omeprazole; Drug: Melatonin
Sponsors: Aragon Institute of Health Sciences; Aragon Institute of Health Sciences
Not yet recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Conditions: Hyper IgD Syndrome; Mevalonate Kinase Deficiency
Intervention:
Sponsors: Michigan Technological University; Michigan Technological University
Recruiting - verified March 2012 - Condition: Parkinson Disease
Intervention:
Sponsors: University of Michigan; University of Michigan
Recruiting - verified April 2012 - Condition: Congenital Heart Defects
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Recruiting - verified March 2012 - Condition: Spinal Cord Injury
Interventions: Drug: Lidocaine lubricant; Other: Placebo lubricant
Sponsors: Simon Fraser University; Simon Fraser University; University of British Columbia
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Alzheimer's Disease
Intervention: Other: Ophthalmological examination & Questionnaire
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Not yet recruiting - verified April 2012 - Condition: X-linked Hypohidrotic Ectodermal Dysplasia
Intervention: Drug: EDI200
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Not yet recruiting - verified March 2012 - Conditions: Facial Injuries; Adipose Tissue
Intervention: Procedure: Fat graft surgical procedure
Sponsors: University of Pittsburgh; University of Pittsburgh; Department of Defense
Recruiting - verified March 2012 - Conditions: Chronic Obstructive Pulmonary Disease; Neuromuscular Disease; Chest Wall Disorders; Obesity Hypoventilation Syndrome
Interventions: Device: Telemonitoring tools; Device: Usual Care
Sponsors: Hospital Sao Joao; Hospital Sao Joao
Not yet recruiting - verified March 2012 - Conditions: Carney Complex; Gastrointestinal Stromal Tumor; Paraganglioma; Sarcoma
Interventions: Drug: linsitinib; Genetic: nucleic acid sequencing; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: western blotting; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: positron emission tomography; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Basal Cell Nevus Syndrome; Gorlin's Syndrome
Interventions: Drug: GDC-0449; Procedure: Aminolevulinic acid %20 topical solution + blue light
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; Genentech
Not yet recruiting - verified March 2012 - Condition: Duodenal Diseases
Intervention: Other: Tissue Sampling
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Red Blood Cell Folate
Interventions: Dietary Supplement: Folic acid; Dietary Supplement: L-5-MTHF; Other: Placebo
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified March 2012 - Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Dystrophinopathy
Intervention: Drug: Ataluren
Sponsors: PTC Therapeutics; PTC Therapeutics
Not yet recruiting - verified March 2012 - Conditions: Plaque Psoriasis; Crohn's Disease
Interventions: Drug: Adalimumab; Device: Capsule endoscopy
Sponsors: Innovaderm Research Inc.; Innovaderm Research Inc.; Abbott
Not yet recruiting - verified March 2012 - Condition: Cardiomegaly
Intervention: Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Isolated Clubfoot
Intervention: Device: Foot Abduction Brace (FAB)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Shriners Hospitals for Children
Not yet recruiting - verified March 2012 - Condition: Heart Disease Congenital Complex
Interventions: Drug: Hydrocortisone; Drug: Normal Saline
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified May 2012 - Conditions: Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: eltrombopag olamine; Procedure: standard follow-up care
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Intervention: Drug: Temozolomide
Sponsors: Stanford University; Stanford University; Merck
Not yet recruiting - verified March 2012 - Condition: Oral Tumor
Intervention:
Sponsors: University of Bari; University of Bari
Recruiting - verified March 2012 - Condition: Epidermolysis Bullosa Simplex Dowling Meara
Intervention: Procedure: Taking of liquid and top of blisters
Sponsors: Centre Hospitalier Universitaire de Nice; Centre Hospitalier Universitaire de Nice
Recruiting - verified March 2012 - Conditions: Pituitary Adenoma; Pituitary Tumor
Intervention:
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; de Novo Myelodysplastic Syndromes; Noncontiguous Stage II Adult Burkitt Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Stage I Adult Burkitt Lymphoma; Stage III Adult Burkitt Lymphoma; Stage IV Adult Burkitt Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: rasburicase; Drug: allopurinol; Drug: rasburicase
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Condition: Stage IV Lung Cancer
Interventions: Drug: Gefitinib; Drug: Fulvestrant; Drug: Erlotinib
Sponsors: Intergroupe Francophone de Cancerologie Thoracique; Intergroupe Francophone de Cancerologie Thoracique
Not yet recruiting - verified March 2012 - Conditions: Multiple Sclerosis; Chronic Cerebrospinal Venous Insufficiency
Intervention: Procedure: percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency
Sponsors: University of Stirling; University of Stirling
Not yet recruiting - verified March 2012 - Condition: Monitoring of Patients Following Surgery
Intervention: Device: Fitting of a wireless telemetry device
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; Engineering and physical sciences research council; King's College London; University of Oxford
Not yet recruiting - verified March 2012 - Conditions: Heart Defects, Congenital; Surgery
Interventions: Device: NivNava; Device: Cpap
Sponsors: Cliniques universitaires Saint-Luc- Université Catholique de Louvain; Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Recruiting - verified April 2012 - Condition: The Elderly of 75 Years and Living in Nursing Homes
Intervention: Other: It will then allow them to intervene at the right time and the right place
Sponsors: University Hospital, Limoges; University Hospital, Limoges
Not yet recruiting - verified March 2012 - Condition: Coronary Artery Disease
Interventions: Drug: Bivalirudin; Drug: Unfractioned Heparin
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified March 2012 - Conditions: Congenital Heart Disease; Pulmonary Arterial Hypertension
Intervention: Drug: Sildenafil singly or in association with Bosentan
Sponsors: University of Sao Paulo General Hospital; University of Sao Paulo General Hospital; Instituto do Coracao; Fundação de Amparo à Pesquisa do Estado de São Paulo
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Intervention: Drug: Sevelamer carbonate
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Netherton Syndrome
Intervention: Genetic: One 5cm2 autologous skin sheet graft
Sponsors: Great Ormond Street Hospital for Children NHS Trust; Great Ormond Street Hospital for Children NHS Trust
Not yet recruiting - verified March 2012 - Condition: Microcephaly
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified February 2012 - Conditions: Stenosis of Arteriovenous Dialysis Fistula; Arteriovenous Graft Stenosis
Interventions: Device: Conventional PTA; Device: Drug Eluting Balloon (DEB)
Sponsors: Singapore General Hospital; Singapore General Hospital; National Medical Research Council
Recruiting - verified March 2012 - Condition: HIV Infection
Intervention: Drug: stop statin and switch to an antiretroviral drug with less impact on lipid metabolism
Sponsors: University Hospital, Geneva; Calmy Alexandra; Janssen-Cilag A.G., Switzerland
Recruiting - verified February 2012 - Condition: Healthy
Interventions: Drug: Placebo to BI 1021958; Drug: BI 1021958; Drug: BI 1021958
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pedophilia
Intervention: Behavioral: neuropsychological questionnaires
Sponsors: University Hospital, Montpellier; University Hospital, Montpellier
Recruiting - verified February 2012 - Condition: Patent Foramen Ovale
Intervention: Device: PFO device closure
Sponsors: CardioVascular Research Foundation, Korea; Duk-Woo Park
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)
Sponsors: Alliancells Bioscience Corporation Limited; Alliancells Bioscience Corporation Limited
Not yet recruiting - verified March 2012 - Conditions: Pulmonary Disease; Pulmonary Hypertension
Intervention: Radiation: 99mTC-PulmoBind
Sponsors: Montreal Heart Institute; Montreal Heart Institute
Recruiting - verified February 2012 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: trebananib; Drug: cytarabine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Knee Osteoarthritis
Interventions: Other: Usual spa protocol; Other: Active spa protocol
Sponsors: Central Hospital, Nancy, France; Central Hospital, Nancy, France
Recruiting - verified March 2012 - Condition: Missing Teeth
Interventions: Device: Autogenous bone graft; Drug: InductOs; Procedure: Augmentation surgery
Sponsors: University of Zurich; University of Zurich
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: tacrolimus; Biological: rituximab; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Patent Ductus Arteriosus
Interventions: Drug: Oral paracetamol; Drug: Oral ibuprofen
Sponsors: Zekai Tahir Burak Maternity and Teaching Hospital; Zekai Tahir Burak Maternity and Teaching Hospital
Recruiting - verified February 2012 - Conditions: Obese; Disorder of Vitamin C; Growth Hormone Secretion Abnormality
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Vitamin C 250 mg once daily; Dietary Supplement: Vitamin C 1,000 mg once daily
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified March 2012 - Condition: Parkinson's Disease
Intervention:
Sponsors: Helsinki University Central Hospital; Helsinki University Central Hospital; Jorvi Hospital; Hyvinkää Hospital; Institute of Biotechnology, University of Helsinki
Recruiting - verified February 2012 - Condition: Obstructive Lesions of Arteriovenous Dialysis Fistulae
Interventions: Device: PTA Balloon catheter with paclitaxel; Procedure: Plain Balloon angioplasty (PBA)
Sponsors: N.M.B. Medical Applications Ltd; N.M.B. Medical Applications Ltd
Not yet recruiting - verified February 2012 - Conditions: Diseases of Mitral Valve; Aortic Valve Disorder; Atrial Septal Defects; Intracardiac Myxoma
Interventions: Drug: Articaine hydrochloride 2% solution; Drug: Sodium Chloride
Sponsors: Helsinki University Central Hospital; Helsinki University Central Hospital
Recruiting - verified April 2012 - Condition: Patent Ductus Arteriosus
Interventions: Drug: Oral paracetamol; Drug: Oral ibuprofen
Sponsors: Zekai Tahir Burak Maternity and Teaching Hospital; Zekai Tahir Burak Maternity and Teaching Hospital
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Nilotinib; Drug: Matching placebo to Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Systemic Lupus Erythematosus; Pregnancy
Intervention: Drug: belimumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Sturge Weber Syndrome; Port Wine Mark
Interventions: Drug: Timolol; Drug: Balanced salt ophthalmic solution
Sponsors: Wills Eye; Wills Eye; University of Medicine and Dentistry New Jersey
Not yet recruiting - verified February 2012 - Condition: HIV-1
Interventions: Drug: EFV/FTC/TDF + Losartan; Drug: EFV/FTC/TDF; Drug: FTC/TDF + MK-0518; Drug: FTC/TDF+MK-0518+Losartan
Sponsors: Hospital Clinic of Barcelona; Hospital Clinic of Barcelona
Not yet recruiting - verified January 2012 - Condition: Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Intervention: Drug: CO-1686
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified March 2012 - Condition: Functional Gastrointestinal Disorders
Interventions: Drug: Amoxicillin; Other: Placebo
Sponsors: Nationwide Children's Hospital; Nationwide Children's Hospital
Recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Previously Treated Myelodysplastic Syndromes; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: atorvastatin calcium; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Otitis Media; Cleft Palate
Intervention: Procedure: palatoplasty
Sponsors: Children's Hospital of Pittsburgh; Children's Hospital of Pittsburgh; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified February 2012 - Condition: Infertility
Interventions: Drug: Metformin; Drug: Clomiphene citrate
Sponsors: The Egyptian IVF-ET Center; The Egyptian IVF-ET Center
Recruiting - verified February 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Sepsis; Inflammation; Shock
Intervention:
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; The Physicians' Services Incorporated Foundation
Not yet recruiting - verified February 2012 - Condition: Normal Left Ventricular Function
Intervention:
Sponsors: University of Ottawa Heart Institute; University of Ottawa Heart Institute
Recruiting - verified January 2012 - Conditions: Angiofibromas; Tuberous Sclerosis
Interventions: Drug: Placebo; Drug: Rapamycin; Drug: Rapamycin
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2012 - Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: quality-of-life assessment; Other: counseling intervention; Behavioral: exercise intervention; Other: educational intervention; Procedure: standard follow-up care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Conditions: Silver Russell Syndrome; Prader-Willi Syndrome
Interventions: Drug: Anastrozole; Drug: Placebo
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified January 2012 - Conditions: Carcinoma, Non-small Cell Lung; Melanoma
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Alagille Syndrome
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012 - Condition: Autism Spectrum Disorders
Intervention:
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified January 2012 - Conditions: Advanced Solid Tumors; Lymphomas
Intervention: Drug: Alisertib
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Donnai Barrow Syndrome
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Hodgkin's Lymphoma
Interventions: Drug: brentuximab vedotin (SGN-35); Drug: Brentuximab Vedotin (SGN-35)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Seattle Genetics, Inc.
Recruiting - verified January 2012 - Condition: Arteriovenous Fistula
Intervention:
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified January 2012 - Conditions: Endocrine Disease; Infertility; Hypogonadism; Amenorrhea; Adolescents
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Massachusetts General Hospital, Boston, MA
Recruiting - verified November 2011 - Condition: Infectious Complications After Colorectal Surgery
Intervention: Biological: C-reactive protein and procalcitonin dosages
Sponsors: Centre Hospitalier Universitaire Dijon; Centre Hospitalier Universitaire Dijon
Recruiting - verified December 2011 - Condition: Inflammatory Rheumatism
Intervention: Behavioral: Telenursing
Sponsors: University of Applied Sciences of Western Switzerland; University of Applied Sciences of Western Switzerland; Swiss National Science Foundation; Réseau d'Etudes aux Confins de la Santé et du Social (RECSS)(HES-SO); University of Lausanne Hospitals; Consultation Multisite Romande de Rhumatologie Pédiatrique; Ligue Genevoise contre le Rhumatisme
Recruiting - verified January 2012 - Conditions: Osteoarthritis of the Knee; Coagulopathy
Intervention: Drug: PENNSAID (diclofenac sodium solution topical)
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; Covidien; Arthritis Treatment Center, Maryland
Recruiting - verified February 2012 - Conditions: Insulin Resistance; Oligospermia; Azoospermia
Interventions: Other: blood samples; Other: Blood samples
Sponsors: The Egyptian IVF-ET Center; The Egyptian IVF-ET Center
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Not yet recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: BI 409306; Drug: BI 409306; Drug: BI 409306; Drug: BI 409306; Drug: BI 409306 Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel XRP6258; Drug: Abiraterone acetate
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011 - Condition: Heart Failure
Interventions: Drug: Atorvastatin; Drug: Placebo
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified November 2011 - Condition: Gastroschisis
Interventions: Procedure: silo; Procedure: Primary closure for gastroschisis
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City
Recruiting - verified January 2012 - Conditions: Ulcerative Colitis; Crohn's Colitis
Interventions: Procedure: Colonoscopy with Indigo-Carmine chromoendoscopy; Procedure: Conventional white-light colonoscopy
Sponsors: Karolinska University Hospital; Karolinska University Hospital
Recruiting - verified January 2012 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Drug: CP-690,550; Drug: CP-690, 550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Hepatitis B; Renal Failure With Tubular Necrosis
Intervention: Biological: plasma and urine samples, sample with ADN
Sponsors: University Hospital, Limoges; University Hospital, Limoges
Recruiting - verified December 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Conditions: Leukemia; Leukemia, Lymphocytyc; CLL (Chronic Lymphocytic Leukemia); SLL (Small Lymphocytic Lymphoma)
Intervention: Drug: PCI 32765
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2011 - Condition: Urogenital Abnormalities
Intervention: Drug: CDB-2914
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified September 2011 - Condition: Syncope
Intervention:
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Not yet recruiting - verified December 2011 - Condition: Cleft Palate
Interventions: Drug: Oral acetaminophen; Drug: Ofirmev®; Drug: Opioid only
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified December 2011 - Condition: Patent Ductus Arteriosus
Intervention:
Sponsors: Albany Medical College; Albany Medical College; Alere, Inc.
Recruiting - verified December 2011 - Conditions: HIV Infections; Tuberculosis
Interventions: Drug: Isoniazid (INH); Drug: Placebo for isoniazid (INH)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Congenital Uterine Anomalies
Intervention:
Sponsors: University of Nottingham; University of Nottingham
Not yet recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention:
Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Centre Hospitalier Universitaire de Saint Etienne; Institut de Cancérologie de la Loire; Groupe de Recherche sur la Thrombose (GRT)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Other: 3D HI and SHI of ultrasound contrast agent
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Cancer Institute (NCI); Lantheus Medical Imaging; University of California, San Diego
Recruiting - verified December 2011 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Irritable Bowel Syndrome; Non Cardiac Chest Pain; Cyclical Vomiting Syndrome; Functional Dyspepsia; Gastroparesis; Ulcerative Colitis; Vulvodynia; Crohn's Disease
Intervention:
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Condition: Maxillofacial Abnormalities
Intervention:
Sponsors: University of Sao Paulo; University of Sao Paulo
Not yet recruiting - verified December 2011 - Condition: Actinic Keratosis
Interventions: Drug: SR-T100 gel; Drug: Vehicle gel
Sponsors: G&E Herbal Biotechnology Co., LTD; G&E Herbal Biotechnology Co., LTD
Recruiting - verified March 2012 - Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Condition: COPD
Interventions: Drug: GSK573719/GW642444; Drug: GSK573719
Sponsors: Queen's University; Queen's University; GlaxoSmithKline
Not yet recruiting - verified December 2011 - Conditions: Coronary Artery Disease; Myocardial Perfusion Abnormalities
Intervention: Drug: Regadenoson; Optison
Sponsors: University of Nebraska; Thomas R. Porter, MD; Astellas Pharma US, Inc.; GE Healthcare
Not yet recruiting - verified December 2011 - Condition: Zygomatic Fractures
Interventions: Procedure: Navigation Surgery; Procedure: Traditional Surgery
Sponsors: Peking University; Peking University
Recruiting - verified December 2011 - Conditions: Congenital Heart Disease; Cardiac Catheterization
Interventions: Drug: saline with propofol; Drug: ketamine with propofol; Drug: ketamine with propofol
Sponsors: Ibaraki Children's Hospital; Ibaraki Children's Hospital
Recruiting - verified January 2012 - Conditions: Congenital Cerebellar Ataxias; Early-onset Cerebellar Ataxias
Intervention: Genetic: blood sample
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified December 2011 - Conditions: Hereditary Hemorrhagic Telangiectasia; Epistaxis
Intervention: Drug: Thalidomide
Sponsors: IRCCS Policlinico S. Matteo; IRCCS Policlinico S. Matteo
Recruiting - verified December 2011 - Condition: Hemorrhagic Hereditary Telangiectasia
Intervention: Drug: Bevacizumab
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified December 2011 - Conditions: Adrenal Hyperplasia, Congenital; Congenital Hypothyroidism; Cystic Fibrosis
Intervention:
Sponsors: Luminex Molecular Diagnostics; Luminex Corporation
Recruiting - verified January 2012 - To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCondition: Thyroid Cancer
Interventions: Drug: 300mg vandetanib; Drug: 150mg vandetanib
Sponsors: AstraZeneca; AstraZeneca
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: BMS-650032 (Asunaprevir)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Acute Kidney Injury
Interventions: Drug: heparinized saline priming group; Drug: nafamostat infusion after heparinized saline priming
Sponsors: Seoul National University Hospital; Seoul National University Hospital; SK Chemicals Co.,Ltd.
Recruiting - verified April 2012 - Condition: Systemic Sclerosis
Intervention: Other: Magnetic resonance Imaging
Sponsors: University Hospital, Lille; University Hospital, Lille
Recruiting - verified November 2010 - Conditions: Metastatic Solid Tumor; Breast Cancer; Ovarian Cancer
Intervention: Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified May 2012 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib; Drug: Pralatrexate; Drug: Romidepsin; Drug: Gemcitabine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Myocardial Infarction
Intervention:
Sponsors: Interventional Cardiology Research; Interventional Cardiology Research; University of British Columbia
Not yet recruiting - verified December 2011 - Condition: Pectus Excavatum
Interventions: Drug: Desflurane; Drug: Sevoflurane
Sponsors: The Catholic University of Korea; The Catholic University of Korea
Recruiting - verified December 2011 - Condition: Secondary Hyperparathyroidism
Intervention: Drug: Cinacalcet HCl
Sponsors: Istituto Giannina Gaslini; ENRICO VERRINA
Recruiting - verified November 2011 - Conditions: Familial Adenomatous Polyposis; Attenuated Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012 - Condition: Clubfoot
Intervention:
Sponsors: Shriners Hospitals for Children; Shriners Hospitals for Children; Kosair Charities, Inc.
Recruiting - verified November 2011 - Condition: 21-hydroxylase Deficiency
Intervention: Drug: Abiraterone acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: AIN457 (secukinumab); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Patent Ductus Arteriosus
Intervention: Device: Occlutech PDA occluder
Sponsors: Occlutech International AB; Occlutech International AB
Recruiting - verified December 2011 - Conditions: Morbid Obesity; Endometrial Pathology; Menstrual Irregularities
Intervention:
Sponsors: University of Virginia; University of Virginia
Recruiting - verified November 2011 - Conditions: Bundle-Branch Block; Heart Septal Defects, Ventricular
Interventions: Procedure: Echocardiography at rest; Procedure: Echocardiography during exercise; Procedure: MRI at rest; Procedure: Exercise testing
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified November 2011 - Conditions: Impaired Oxygen Delivery; Congenital Heart Disease
Interventions: Other: Red blood cell transfusion; Other: Red blood cell transfusion
Sponsors: University of Rochester; University of Rochester
Not yet recruiting - verified November 2011 - Condition: Major Depressive Disorder
Intervention:
Sponsors: University of Utah; Paul Carlson; Western Institute for Biomedical Research; Brain Institute, University of Utah; University of Utah; Molecular Imaging Program, Huntsman Cancer Institute
Recruiting - verified November 2011 - Condition: Gastroschisis
Intervention:
Sponsors: Children's Hospitals and Clinics of Minnesota; Children's Hospitals and Clinics of Minnesota
Recruiting - verified November 2011 - Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012 - Condition: Chronic Kidney Disease
Intervention:
Sponsors: Baptist Hospital of Miami; Baptist Hospital of Miami
Recruiting - verified December 2011 - Conditions: Esophageal Atresia With Tracheo-esophageal Fistula; Congenital Diaphragmatic Hernia
Interventions: Procedure: Hypercapnia during thoracoscopy; Procedure: Open surgery
Sponsors: Great Ormond Street Hospital for Children NHS Trust; Great Ormond Street Hospital for Children NHS Trust
Recruiting - verified November 2011 - Conditions: Metabolic Syndrome; Type 2 Diabetes; Cardiovascular Disease; Abdominal Obesity
Interventions: Dietary Supplement: High content of SMC-SFA; Dietary Supplement: Whey; Dietary Supplement: Low content of SMC-SFA; Dietary Supplement: Casein
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital; Arla Foods; Wageningen University; University of Dublin, Trinity College
Recruiting - verified February 2012 - Conditions: End Stage Renal Disease; AV Fistula; Kidney Failure
Intervention: Device: Venous Window Needle Guide
Sponsors: Vital Access Corp.; Vital Access Corp.
Recruiting - verified January 2012 - Condition: Asthma
Intervention: Drug: Budesonide
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Heart Defects, Congenital
Intervention: Behavioral: Structured exercise training
Sponsors: University Hospital, Basel, Switzerland; University Hospital, Basel, Switzerland
Recruiting - verified October 2011 - Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Hepatopulmonary Syndrome; Liver Cirrhosis
Interventions: Drug: bosentan; Drug: Placebo
Sponsors: Medical University of Vienna; Medical University of Vienna
Recruiting - verified January 2012 - Conditions: Left Ventricular Noncompaction; Isolated Noncompaction of the Ventricular Myocardium
Intervention:
Sponsors: University of Zurich; University of Zurich
Recruiting - verified November 2011 - Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012 - Condition: Bipolar Disorder
Intervention: Drug: Asenapine
Sponsors: University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University
Recruiting - verified May 2012 - Condition: Congenital Glaucoma
Interventions: Procedure: Deep Sclerectomy; Procedure: Combined Trab
Sponsors: King Saud University; King Saud University
Not yet recruiting - verified October 2011 - Condition: Conotruncal Cardiac Defects
Intervention: Biological: Bood sampling for biochemicals and genetic analysis
Sponsors: Central Hospital, Nancy, France; Central Hospital, Nancy, France; Centre Hospitalier Universitaire de Besancon; University Hospital, Strasbourg, France; Centre Hospitalier Universitaire Dijon; CHU de Reims
Recruiting - verified October 2011 - Conditions: Pain; Migraine Disorders
Interventions: Biological: PF-04427429; Other: Normal saline
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: PF-00299804 Plus Blinded Doxycycline Placebo; Drug: PF-00299804 Plus Blinded Doxycycline; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: Salbutamol
Sponsors: Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-790052; Drug: BMS-790052; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Behavioral: Structured Lifestyle Education
Sponsors: University of Leicester; University of Leicester; Society for Endocrinology
Recruiting - verified October 2011 - Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
Sponsors: Grupo Espanol de trasplantes hematopoyeticos y terapia celular; Grupo Espanol de trasplantes hematopoyeticos y terapia celular; GlaxoSmithKline
Recruiting - verified January 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia
Intervention: Drug: bortezomib
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Overweight/Obese Women
Intervention: Other: High Fat Diet
Sponsors: University of Michigan; University of Michigan; Robert C. Atkins Foundation
Recruiting - verified October 2011 - Conditions: Impaired Oxygen Delivery; Ischemic Reperfusion Injury
Intervention: Behavioral: exercise
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Recruiting - verified September 2010 - Conditions: Renal Failure Chronic Requiring Hemodialysis; Metabolic Syndrome; Diabetes Mellitus Type 2; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: Poznan University of Medical Sciences; Poznan University of Medical Sciences
Recruiting - verified October 2011 - Condition: Autism Spectrum Disorders
Intervention:
Sponsors: The Cleveland Clinic; The Cleveland Clinic; National Institutes of Health (NIH); National Center for Research Resources (NCRR)
Recruiting - verified October 2011 - Conditions: Healthy; Hepatic Impairment
Intervention: Drug: cabozantinib
Sponsors: Exelixis; Exelixis
Recruiting - verified December 2011 - Condition: Fetal Complications
Intervention:
Sponsors: Aria Diagnostics, Inc.; Aria Diagnostics, Inc.
Recruiting - verified January 2012 - Conditions: Hypospadia; Phimosis; Inguinal Hernia
Intervention:
Sponsors: RenJi Hospital; RenJi Hospital; Shanghai Children's Medical Center
Recruiting - verified March 2012 - Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD; Drug: darunavir 800mg OAD; Drug: ritonavir 100mg OAD
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Cholestasis of Pregnancy
Intervention:
Sponsors: Imperial College London; Imperial College London
Recruiting - verified December 2011 - Condition: Congenital Heart Diseases
Interventions: Drug: Sevoflurane; Other: Control
Sponsors: Xijing Hospital; Xijing Hospital
Recruiting - verified November 2011 - Condition: Adolescent Idiopathic Scoliosis
Intervention: Device: Gelatin matrix with human derived thrombin (Floseal, Baxter)
Sponsors: Turku University Hospital; Turku University Hospital; Tampere University Hospital; Helsinki University Central Hospital
Recruiting - verified September 2011 - Conditions: Congenital Heart Defects; Growth Failure
Interventions: Other: Arm 1: NPO by mouth pre-operative; Other: Arm 2: Fresh Breast Milk pre-operative
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified November 2011 - Condition: Prader-Willi Syndrome
Intervention: Drug: Exenatide
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Spinal Cord Injury
Intervention:
Sponsors: University of Miami; Clinical Research Initiation Services
Recruiting - verified November 2011 - Conditions: Scoliosis; Kyphoscoliosis
Intervention: Procedure: Surgical correction of the deformity
Sponsors: Istituto Ortopedico Rizzoli; Istituto Ortopedico Rizzoli
Recruiting - verified July 2011 - Condition: Junctional Kyphosis
Interventions: Device: Semi rigid rod; Device: Rigid Rod
Sponsors: Globus Medical Inc; Globus Medical Inc; University of California, San Francisco; Carolina Neurosurgery & Spine Associates; University of Michigan; Peachtree Neurosurgery Atlanta, GA; Copenhagen University Hospital, Denmark; Scott and White Hospital & Clinic
Not yet recruiting - verified September 2011 - Conditions: Addison's Disease; Adrenal Insufficiency; Diabetes Mellitus Type I
Intervention: Procedure: Spiroergometry
Sponsors: University of Wuerzburg; University of Wuerzburg
Recruiting - verified October 2011 - Condition: Tricuspid Valve Insufficiency
Intervention:
Sponsors: Universitaire Ziekenhuizen Leuven; Pieter De Meester
Not yet recruiting - verified September 2011 - Condition: Kawasaki Disease
Intervention: Other: Cardiac evaluation
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified September 2011 - Conditions: Osteoarthritis; Avascular Necrosis; Rheumatoid Arthritis; Developmental Dysplasia of the Hip
Intervention:
Sponsors: Wirral University Teaching Hospital NHS Trust; Hussain Kazi
Not yet recruiting - verified September 2011 - Conditions: Castleman Disease; Castleman's Disease; Giant Lymph Node Hyperplasia
Interventions: Drug: Zidovudine; Drug: Tocilizumab; Drug: Valganciclovir
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Port Wine Stain
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Brigham and Women's Hospital
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Dietary Supplement: Pistachios; Other: control diet
Sponsors: Institut Investigacio Sanitaria Pere Virgili; Institut Investigacio Sanitaria Pere Virgili; Western Pistachio Association
Recruiting - verified September 2011 - Condition: Hypertension
Intervention:
Sponsors: Medical Universtity of Lodz; Medical Universtity of Lodz
Not yet recruiting - verified October 2011 - Conditions: Solid Tumors; Hepatic Impairment
Intervention: Drug: Dovitinib
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012 - Condition: Kawasaki Disease
Intervention: Drug: Atorvastatin
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified September 2011 - Condition: Heart Disease
Interventions: Procedure: Rb-82 and N-13 ammonia imaging; Procedure: F-18 FDG imaging
Sponsors: University of Michigan; University of Michigan
Recruiting - verified September 2011 - Condition: Chronic Hepatitis B
Interventions: Drug: Adefovir Dipivoxil and polyene phosphatidylcholine; Drug: Adefovir Dipivoxil
Sponsors: Capital Medical University; Jun Cheng; Sanofi-Aventis; Fujian Cosunter Pharmaceutical Co. Ltd
Not yet recruiting - verified September 2011 - Condition: Stress Induced Cardiomyopathy
Intervention: Drug: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Sponsors: University of Pittsburgh; University of Pittsburgh; GE Healthcare
Recruiting - verified September 2011 - Condition: Hypoplastic Left Heart Syndrome
Interventions: Other: Autologous Umbilical Cord Blood; Other: Autologous Umbilical Cord Blood
Sponsors: Duke University; Duke University
Recruiting - verified September 2011 - Condition: Prostate Cancer
Interventions: Drug: metformin; Drug: Placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); University of Arizona
Not yet recruiting - verified October 2011 - Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS); Duke University; Children's Hospital of Michigan; Baylor College of Medicine; Texas Children's Hospital; Wills Eye; Nationwide Children's Hospital
Recruiting - verified February 2012 - Conditions: Sleep Apnea; Heart Failure
Interventions: Procedure: Nocturnal nasal oxygen; Other: No nasal oxygen
Sponsors: University of Maryland; University of Maryland
Recruiting - verified May 2012 - Conditions: Preterm Infants; Post Traumatic Stress Disorder; Emotional Stress; Infant, Very Low Birth Weight
Intervention:
Sponsors: Sheba Medical Center; Sheba Medical Center
Recruiting - verified September 2011 - Condition: Psoriasis
Interventions: Drug: CNTO 1959; Drug: Placebo
Sponsors: Janssen Pharmaceutical K.K.; Janssen Pharmaceutical K.K.
Recruiting - verified April 2012 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Metformin; Drug: Progesterone; Drug: estrace
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Progesterone; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Condition: Chronic Cerebrospinal Venous Insufficiency
Interventions: Other: Doppler sonography of internal jugular veins; Other: Magnetic resonance venography of internal jugular veins; Other: Air-plethysmography of the neck; Other: Catheter venography of internal jugular veins
Sponsors: Euromedic Specialist Clinics, Poland; Euromedic Specialist Clinics, Poland
Recruiting - verified August 2011 - Condition: Scar
Interventions: Drug: Botulinum Toxin Type A; Drug: Botulinum Type A; Drug: Normal Saline; Drug: Normal Saline
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Recruiting - verified August 2011 - Conditions: Hemophilia A; Hemophilia B
Interventions: Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Non-24-Hour Sleep-Wake Disorder
Interventions: Drug: Tasimelteon; Drug: Placebo
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified January 2012 - Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Prematurity of Fetus; Patent Ductus Arteriosus
Interventions: Drug: Indomethacin; Procedure: Surgical Ligation
Sponsors: University of Ulm; University of Ulm
Recruiting - verified August 2011 - Condition: Multiple Sclerosis
Intervention: Drug: AIN457
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Obese; Growth Hormone Secretion Abnormality
Intervention: Drug: Growth hormone treatment
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Pfizer
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Genetic: DNA methylation analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: nucleic acid sequencing; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified August 2011 - Condition: Leukemia
Interventions: Genetic: DNA methylation analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Not yet recruiting - verified August 2011 - Condition: Leukemia
Interventions: Drug: bortezomib; Drug: decitabine
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012 - Conditions: Spontaneous Intracerebral Hemorrhage; Ischemic Strokes; Diffusion Weighted Imaging Lesions
Intervention:
Sponsors: Rush University Medical Center; Rush University Medical Center; American Heart Association
Recruiting - verified January 2012 - Conditions: KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir; Drug: Rituximab/Liposoma Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Condition: Thoracic Surgery
Interventions: Drug: Desflurane; Drug: Propofol
Sponsors: University of Zurich; University of Zurich
Not yet recruiting - verified October 2011 - Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma; Leukemia, Prolymphocytic
Intervention: Drug: auranofin
Sponsors: University of Kansas; University of Kansas; The Leukemia and Lymphoma Society; Kansas Bioscience Authority; Therapeutics for Rare and Neglected Diseases (TRND)
Recruiting - verified October 2011 - Conditions: Healthy Volunteers; Atopic Dermatitis; Netherton Syndrome
Interventions: Drug: BPR277 ointment (controlled application); Drug: Placebo (Vehicle); Drug: BPR277 ointment; Drug: Placebo (Vehicle); Drug: BPR277; Drug: Placebo (Vehicle)
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Condition: Hypotension
Intervention: Device: Ultrasound
Sponsors: Saint John Regional Hospital; Saint John Regional Hospital
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: tacrolimus; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified April 2012 - Condition: Digestive System Abnormalities
Intervention:
Sponsors: Goethe University; Goethe University
Recruiting - verified October 2011 - Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011 - Condition: Tetralogy of Fallot
Intervention: Device: Ventripoint Medical System
Sponsors: VentriPoint Diagnostics Ltd.; VentriPoint Diagnostics Ltd.
Recruiting - verified March 2012 - Conditions: Obesity; Cardiovascular Abnormalities
Intervention:
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified July 2011 - Condition: Heart Failure
Intervention: Drug: Pyridostigmine Bromide
Sponsors: New York University School of Medicine; New York University School of Medicine; Nathan Kline Institute for Psychiatric Research; Oklahoma State University Center for Health Sciences; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified August 2011 - Conditions: Interleukin 7; Diabetes; Islet Transplantation; Kidney Transplantation; Liver Transplantation
Intervention: Procedure: transplantation
Sponsors: University Hospital, Lille; University Hospital, Lille
Recruiting - verified September 2011 - Condition: Hysterical Simulation of Disease
Interventions: Device: Functional electrical stimulator; Device: feet orthosis
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified July 2011 - Condition: Coronary Artery Disease
Intervention: Radiation: 1/2 dose of 99mTc OR 201Tl tracers
Sponsors: University of Ottawa Heart Institute; University of Ottawa Heart Institute
Recruiting - verified August 2011 - Conditions: Pregnancy; Fetal Health
Intervention:
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; Empire Clinical Research Investigator program
Recruiting - verified January 2012 - Conditions: Prostate Cancer; Prostate Adenocarcinoma
Interventions: Radiation: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy; Radiation: Standard IMRT; Behavioral: EPIC SF-12 Questionnaire; Behavioral: MAX-PC Questionnaire; Behavioral: IPSS Questionnaire; Procedure: Blood Sample Collection; Procedure: Urine Sample Collection; Procedure: Prostate Biopsy; Procedure: CT Simulation; Procedure: MRI Simulation; Procedure: Fiducial Gold Marker Placement
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Cyanotic Congenital Heart Disease
Interventions: Drug: Topiramate; Other: No medication, but routine heart surgery
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified August 2011 - Condition: HIV-infection
Intervention: Drug: Angiotensin II Infusion
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Conditions: Telangiectasia, Hereditary Hemorrhagic; Epistaxis
Interventions: Drug: Sterile saline; Drug: Bevacizumab; Drug: Estriol; Drug: Tranexamic Acid
Sponsors: Georgia Health Sciences University; James Gossage; Hereditary Hemorrhagic Telangiectasia Foundation International
Recruiting - verified February 2012 - Condition: Oral Mucositis
Interventions: Biological: ALD518; Drug: 0.9% saline
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Cerebral Palsy
Intervention: Biological: CD133 stem cell injection
Sponsors: Royan Institute; Royan Institute
Recruiting - verified August 2010 - Conditions: Hepato/Renal Fibrocystic Disease; Autosomal Recessive Polycystic Kidney Disease; Joubert Syndrome; Bardet Biedl Syndrome; Meckel-Gruber Syndrome; Congenital Hepatic Fibrosis; Caroli Syndrome; Oro-Facial-Digital Syndrome Type I; Nephronophithisis; Glomerulocystic Kidney Disease
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Conditions: Muscular Dystrophy; Congenital Muscular Dystrophy; Fukutin-related Protein Gene; Limb Girdle; FKRP Gene; Childhood Onset LGMD; Adult Onset LGMD; POMT1; POMT2; POMGnT1; LARGE; Alpha Dystroglycan; Dystroglycanopathy; Centronuclear; Multiminicore; Multicore; Minicore; Congenital Fiber Type Disproportion; Myotubular; Nemaline; Congenital Myopathy; Neuromuscular; Rigid Spine; Phenotype-Genotype Correlation; Cough Assisted Device; Neuromuscular Disease; Respiratory Exacerbation; Invasive Ventilation; Chest Physiotherapy; Congenital Myopathies; Genetic Mutations; Hypertrophic Cardiomyopathy; Wheelchair Use; Cataract; Opthalmoplegia; Ullrich Congenital Muscular Dystrophy; Intermediate Collagen VI Myopathy; Laminin Alpha 2 Related Congenital Muscular Dystrophy; MDC1A; Merosin Deficient Congenital Muscular Dystrophy; Congenital Muscular Dystrophy Undiagnosed; Congenital Muscular Dystrophy Merosin Positive; Walker Warburg Syndrome; Muscle Eye Brain Disease; Fukuyama; Integrin Alpha 7 Deficiency; Integrin Alpha 9 Deficiency; Laminopathy; Lamin AC; SEPN 1 Related Myopathies; Bethlem Myopathy; Dystroglycanopathies; LGMD2K; LGMD2I; LGMD2L; LGMD2N; Actin Aggregation Myopathy; Cap Disease; Central Core Disease; Centronuclear Myopathy; Core Rod Myopathy; Hyaline Body Myopathy; Multiminicore Myopathy; Myotubular Myopathy; Nemaline Myopathy; Tubular Aggregate Myopathy; Zebra Body Disease Myopathy; Congenital Myopathy Other; Reducing Body Myopathy; Sarcotubular Myopathy; Spheroid Body Myopathy
Intervention:
Sponsors: Cure CMD; Cure CMD
Recruiting - verified July 2011 - Condition: Infants or Children Undergoing Open Heart Surgery
Interventions: Other: leg elevation; Other: Trendelenburg position; Other: Trendelenburg position + passive leg elevation; Other: control group
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified July 2011 - Conditions: Transfusion-dependent β-thalassemia Patients; Cardiac Iron Overload
Interventions: Drug: Deferasirox; Drug: Deferasirox + Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Acute Coagulopathy
Interventions: Biological: Blood product transfusion based on conventional coagulation tests.; Biological: Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Sponsors: Denver Health and Hospital Authority; Denver Health and Hospital Authority; Haemonetics Corporation
Recruiting - verified February 2012 - Condition: Traumatic and/or Non-traumatic Brain Injury
Intervention:
Sponsors: Sheba Medical Center; Sheba Medical Center
Recruiting - verified May 2012 - Condition: Heart Defects, Congenital
Intervention:
Sponsors: Oslo University Hospital; Oslo University Hospital; Haukeland University Hospital
Recruiting - verified August 2011 - Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Drug: Submucosal Bevacizumab
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified July 2011 - Conditions: Hypohidrotic Ectodermal Dysplasia; X-Linked Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified August 2011 - Condition: Oral Ibuprofen Prophylaxis in Very Low Birth Weight Infants
Interventions: Drug: ibuprofen; Drug: ibuprofen
Sponsors: Zekai Tahir Burak Maternity and Teaching Hospital; Zekai Tahir Burak Maternity and Teaching Hospital
Recruiting - verified July 2011 - Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Drug: Bevacizumab
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified July 2011 - Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients.Condition: Acute Myocardial Infarction
Interventions: Other: Autologous Bone marrow mononuclear cells; Other: Placebo control
Sponsors: TotipotentRX Cell Therapy Pvt. Ltd.; TotipotentRX Cell Therapy Pvt. Ltd.
Not yet recruiting - verified February 2012 - Condition: Hepatic Impairment
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Pulmonary Arterial Hypertension; Eisenmenger Syndrome
Intervention: Other: respiratory and exercise therapy
Sponsors: University of Heidelberg; University of Heidelberg
Recruiting - verified March 2012 - Conditions: Renal Failure; Arteriovenous Fistula
Intervention: Procedure: Active ultrasound surveillance of fistula and proactive treatment of stenosis
Sponsors: University of Hull; University of Hull
Not yet recruiting - verified July 2011 - Condition: Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Other: laboratory biomarker analysis; Genetic: protein expression analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Cardiac Arrhythmia
Intervention: Procedure: ECG electrodes
Sponsors: Mayo Clinic; Mayo Clinic
Not yet recruiting - verified July 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: Metformin ER
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; American Diabetes Association
Recruiting - verified July 2011 - Conditions: Dystrophinopathy; Duchenne Muscular Dystrophy; Becker's Muscular Dystrophy
Intervention: Drug: L-arginine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012 - Condition: Neoplasm Malignant
Intervention: Drug: SAR245408
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Blood Pressure; Heart Rate and Rhythm Disorders; Hypoglycemia; Lactate; Nitrate; Cholesterol (Total and HDL); Abnormality in Fetal Heart Rate or Rhythm, Unspecified as to Episode of Care
Intervention: Other: Physical exercise
Sponsors: Instituto Materno Infantil Prof. Fernando Figueira; Instituto Materno Infantil Prof. Fernando Figueira; Professor Fernando Figueira Integral Medicine Institute; Federal University of Paraíba
Not yet recruiting - verified June 2011 - Conditions: Turner Syndrome; Ovarian Insufficiency
Intervention: Procedure: Ovariectomy
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Groupe Hospitalier Pitie-Salpetriere; Cochin Hospital
Recruiting - verified July 2011 - Conditions: Diabetic Foot Ulcers; Equinus Deformity
Intervention:
Sponsors: Georgetown University; Georgetown University
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Genetic: mutation analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified June 2011 - Conditions: Epistaxis; Hereditary Hemorrhagic Telangiectasia
Intervention: Drug: Sodium tetradecyl sulfate (sotradecol)
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; American Rhinologic Society
Recruiting - verified April 2012 - Conditions: Environmental Pollutants in Follicular Fluids; Female Subfertility; IVF
Intervention:
Sponsors: Infertility Treatment Center Dortmund; Infertility Treatment Center Dortmund
Recruiting - verified June 2011 - Conditions: Foramen Ovale, Patent; Heart Defects, Congenital; Heart Septal Defects
Intervention: Device: Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)
Sponsors: SeptRx, Inc.; SeptRx, Inc.
Recruiting - verified June 2011 - Condition: Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified June 2011 - Conditions: Multiple Sclerosis; Neurodegenerative Diseases
Intervention:
Sponsors: Fondazione Italiana Sclerosi Multipla; Fondazione Italiana Sclerosi Multipla; Opera Srl
Recruiting - verified April 2012 - Condition: Autism
Intervention: Device: Transcranial Magnetic Stimulation
Sponsors: Brainsway; Brainsway; Hadassah Medical Organization
Not yet recruiting - verified July 2011 - Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
Sponsors: Centre Georges Francois Leclerc; Centre Georges Francois Leclerc; AstraZeneca
Recruiting - verified January 2012 - Conditions: Chronic Kidney Disease; Renal Osteodystrophy; Left Ventricular Hypertrophy
Intervention:
Sponsors: RFM Renal Treatment Services; RFM Renal Treatment Services
Not yet recruiting - verified June 2011 - Condition: Parkinson Disease
Interventions: Genetic: Healthy; Genetic: PKD Patients
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012 - Condition: Haemodialysis
Interventions: Drug: Heparin 2,400 IU /ml Cutaneous Spray; Drug: Placebo Cutaneous Spray
Sponsors: Cyathus Exquirere Pharmaforschungsgmbh; Cyathus Exquirere Pharmaforschungsgmbh
Recruiting - verified March 2012 - Conditions: Postherpetic Neuralgia; Healthy Age/Gender Matched Volunteers
Intervention: Other: skin biopsy
Sponsors: Albany Medical College; Albany Medical College; National Institutes of Health (NIH)
Recruiting - verified December 2010 - Conditions: HIV; Human Papillomavirus
Interventions: Biological: Gardasil; Biological: Cervarix
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012 - Conditions: LH Pulsatility; Obesity; Reproduction
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified June 2011 - Conditions: Hip Dislocation, Congenital; Congenital Deformity of Hip Joint
Interventions: Other: Pavlik Brace; Other: Plastizote Brace
Sponsors: OrthoCarolina Research Institute, Inc.; OrthoCarolina Research Institute, Inc.
Recruiting - verified January 2012 - Condition: Chronic Hepatitis
Interventions: Drug: oral antiviral for HBV; Drug: tenofovir disoproxil fumarate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Congenital Heart Defects
Intervention: Procedure: Percutaneous pulmonary valve implantation or open heart surgery
Sponsors: Oslo University Hospital; Oslo University Hospital
Not yet recruiting - verified August 2011 - Condition: SARS
Interventions: Drug: Aluminum hydroxide adjuvant (Alhydrogel®); Biological: Recombinant S protein SARS vaccine; Other: Phosphate buffered saline Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012 - Condition: Hypospadias
Interventions: Drug: promestriene; Drug: Placebo; Procedure: Urethroplasty; Radiation: Wrist X ray; Procedure: Blood test
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified December 2011 - Condition: Tracheobronchomalacia
Intervention: Procedure: Rigid bronchoscopy
Sponsors: Hospital de Clinicas de Porto Alegre; Hospital de Clinicas de Porto Alegre
Recruiting - verified August 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pachyonychia Congenita
Intervention: Drug: Simvastatine
Sponsors: Tel-Aviv Sourasky Medical Center; Tel-Aviv Sourasky Medical Center
Not yet recruiting - verified October 2009 - Conditions: Colonic Polyp; Colon Cancer
Intervention: Other: Sample of polyp
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Conditions: Ehlers Danlos Syndrome; External Hydrocephalus; Dysautonomia; Postural Orthostatic Tachycardia Syndrome; Venous Insufficiency
Intervention:
Sponsors: Genetic Disease Investigators; Genetic Disease Investigators
Recruiting - verified June 2011 - Conditions: Coronary Artery Disease; Proteus Syndrome; Coffin - Sins Syndrome; Familial Isolated Hyperparathyroidism; Dubouitz Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2012 - Condition: Mullerian Duct Anomaly
Intervention: Other: Three-dimensional ultrasound
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified July 2011 - Conditions: Photoparoxysmal Abnormalities; Epilepsy; Seizures
Interventions: Other: Mozart K448; Other: Beethoven's Für Elise; Other: No music exposure
Sponsors: Medical University of South Carolina; Medical University of South Carolina; MIND Research Institute
Recruiting - verified March 2011 - Condition: Coronary Heart Disease
Intervention: Radiation: Computed tomography scan
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Recruiting - verified June 2006 - Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Pediatric Leukemia; Other Pediatric Cancers
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Turner Syndrome
Intervention: Drug: somatotropin
Sponsors: University of North Carolina, Chapel Hill; Marsha Davenport, MD; Pfizer
Recruiting - verified January 2012 - Conditions: Port Wine Stain; Klippel Trenaunay Syndrome; Parkes Weber Syndrome
Intervention: Genetic: search for polymorphisms of RASA1 gene
Sponsors: University Hospital, Tours; University Hospital, Tours
Recruiting - verified June 2011 - Condition: Umbilical Cord
Intervention: Procedure: Doppler ultrasound
Sponsors: Medstar Research Institute; Medstar Research Institute
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel; Drug: Trastuzumab, Docetaxel, Bevacizumab; Drug: Trastuzumab+Docetaxel+NPLD; Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche; Cephalon
Recruiting - verified April 2012 - Condition: Solid Cancers
Interventions: Drug: docetaxel; Drug: GDC-0068; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Not yet recruiting - verified May 2011 - Condition: Leukemia
Interventions: Drug: tipifarnib; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: PSI-7977; Drug: BMS-790052; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BMS-790052; Drug: PSI-7977
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pharmasset
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Genetic: proteomic profiling; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2011 - Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism
Intervention:
Sponsors: Hamilton Health Sciences Corporation; Hamilton Health Sciences Corporation; St. Joseph's Healthcare Hamilton
Not yet recruiting - verified June 2011 - Conditions: Bone Diseases; Obesity; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2012 - Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: secukinumab; Biological: secukinumab; Biological: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Scoliosis
Interventions: Device: Thoraco-lumbo-sacral Orthosis; Other: Watchful waiting
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2011 - Conditions: Non-Hodgkin's Lymphoma; Solid Tumour
Intervention: Drug: GDC-0349
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: naproxen; Drug: esomeprazole
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified June 2011 - Condition: Smith-Lemli-Opitz Syndrome
Intervention: Dietary Supplement: Cholesterol supplementation
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: vildagliptin; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: Axitinib
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564); Biological: Lenalidomide; Biological: Dexamethasone; Biological: Anti-CXCR4 (BMS-936564); Biological: Bortezomib; Biological: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Conditions: Iron Deficiency Anaemia; Inflammatory Bowel Disease; Crohn's Disease
Interventions: Drug: ST10-021; Drug: Placebo Comparator
Sponsors: Iron Therapeutics; Iron Therapeutics; AOP Orphan Pharmaceuticals AG; Shield Holdings
Recruiting - verified December 2011 - Conditions: Basal Cell Carcinoma; Gorlin Syndrome; Nevoid Basal Cell Carcinoma Syndrome
Interventions: Drug: LDE225; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Pre-Eclampsia; Pregnancy; Hypertension
Intervention: Drug: Nifedipine
Sponsors: Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Recruiting - verified March 2012 - Condition: HIV Infection
Interventions: Drug: atazanavir; Drug: atazanavir/ritonavir
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified September 2011 - Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Drug: alvocidib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: mitoxantrone hydrochloride
Sponsors: National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: DDD; Deformity; Tumor; Fracture
Intervention:
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012 - Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine
Sponsors: University of Utah; University of Utah; Celgene Corporation
Recruiting - verified January 2012 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cyclosporine; Drug: pravastatin sodium; Drug: mitoxantrone hydrochloride; Drug: etoposide; Procedure: bone marrow aspiration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2012 - Condition: Missing Teeth
Interventions: Procedure: Zirconia-based adhesive bridge; Procedure: Metal-based adhesive bridge
Sponsors: Queen Mary University of London; Queen Mary University of London
Not yet recruiting - verified January 2011 - Condition: Microvascular Coronary Dysfunction (MCD)
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; University of Florida
Recruiting - verified March 2012 - Conditions: Iron Deficiency Anaemia; Inflammatory Bowel Disease; Ulcerative Colitis
Interventions: Drug: ST10-021; Drug: Placebo Comparator
Sponsors: Iron Therapeutics; Iron Therapeutics; AOP Orphan Pharmaceuticals AG; Shield Holdings
Recruiting - verified December 2011 - Conditions: Infant, Very Low Birth Weight; Infant Malnutrition; Feeding Disorder of Infancy or Early Childhood; Splanchnic Oximetry; Splanchnic Oxygenation
Interventions: Other: different nutrional regimen; Other: comparison of different feeding regimens
Sponsors: San Gerardo Hospital; San Gerardo Hospital
Recruiting - verified March 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BKM120; Drug: fulvestrant; Procedure: biopsy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified October 2011 - Conditions: Age Related Macular Degeneration; Choroidal Neovascularization
Intervention:
Sponsors: Notal Vision Ltd; Notal Vision Ltd
Not yet recruiting - verified February 2012 - Conditions: Infertility; Miscarriage
Intervention: Genetic: Preimplantation Genetic Diagnosis
Sponsors: Reprogenetics; Reprogenetics; Reprogenetics Lationoamerica S.A.C, Lima, Peru; Pranor S.R.L., Lima, Peru; Yale University; McGill University
Recruiting - verified November 2011 - Condition: Diabetic Retinopathy
Intervention:
Sponsors: Medical University of Vienna; Medical University of Vienna
Not yet recruiting - verified April 2011 - Condition: HIV, Combination Therapy
Interventions: Drug: Atazanavir; Drug: Ritonavir (heat-stable); Drug: Raltegravir; Drug: Tenofovir/Emtricitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Scoliosis
Intervention:
Sponsors: Rennes University Hospital; Rennes University Hospital
Recruiting - verified February 2012 - Condition: Lymphedema
Intervention:
Sponsors: Stanford University; Stanford University; Feinstein Institute for Medical Research
Recruiting - verified April 2012 - Condition: Epidermolysis Bullosa
Intervention: Drug: Oral erythromycin
Sponsors: Centre Hospitalier Universitaire de Nice; Centre Hospitalier Universitaire de Nice
Recruiting - verified October 2011 - Condition: Pectus Excavatum
Intervention: Device: Magnetic Mini-Mover Procedure (Magnimplant)
Sponsors: University of California, San Francisco; Michael Harrison; Shriners Hospitals for Children; University of California, Davis
Recruiting - verified February 2012 - Condition: Cushing Disease
Intervention: Drug: LCI699
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: PegIFN/RBV; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Accommodative Insufficiency; Ill-sustained Accommodation
Intervention:
Sponsors: Western University of Health Sciences; Western University of Health Sciences; Southern California College of Optometry
Recruiting - verified November 2011 - Conditions: Multiple Sclerosis; Optic Neuritis
Intervention: Drug: Mangafodipir (Teslascan)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified January 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: Congenital Heart Defect; Surgery-Induced Tissue Adhesions; Hemorrhage
Intervention: Device: CoSeal Surgical Spray Group
Sponsors: Loma Linda University; Loma Linda University; Baxter Healthcare Corporation
Recruiting - verified March 2012 - Condition: Patent Foramen Ovale
Intervention: Device: Cardiox FDS
Sponsors: Cardiox Corporation; Cardiox Corporation
Recruiting - verified May 2012 - Conditions: Marfan Syndrome; Turner Syndrome; Ehlers-Danlos Syndrome; Loeys-Dietz Syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation; Bicuspid Aortic Valve Without Known Family History; Bicuspid Aortic Valve With Family History; Bicuspid Aortic Valve With Coarctation; Familial Thoracic Aortic Aneurysm and Dissections; Shprintzen-Goldberg Syndrome; Other Aneurysms and Dissections of the Thoracic Aorta Not Due to Trauma, <50yo; Other Congenital Heart Disease
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012 - Condition: Non Alcoholic Fatty Liver Diseases (NAFLD)
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Conditions: Arteriovenous Fistula; Fistula
Interventions: Procedure: Cutting balloon angioplasty; Procedure: Angioplasty
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified March 2012 - Condition: Glaucoma
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Eye Institute (NEI)
Recruiting - verified May 2012 - Conditions: Pulmonary Arterial Hypertension; Congenital Heart Disease; Eisenmenger's Syndrome
Intervention: Drug: Iloprost
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Actelion
Recruiting - verified June 2011 - Condition: Infantile Hemangiomas
Interventions: Drug: Timolol 0.5% topical; Drug: Mupirocin
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Society for Pediatric Dermatology
Recruiting - verified August 2011 - Condition: Kabuki Syndrome
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified February 2011 - Osteopathic Manipulation for Female Interstitial Cystitis Patients With Sacroiliac Joint DysfunctionConditions: Interstitial Cystitis; Sacroiliac Joint Dysfunction
Intervention: Procedure: Osteopathic Manipulation Therapy
Sponsors: Pelvic and Sexual Health Institute; Pelvic and Sexual Health Institute; Interstitial Cystitis Association
Recruiting - verified December 2011 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Adrenal Hyperplasia; Polycystic Ovarian Syndrome; Oligomenorrhea; Obesity; Hyperandrogenism
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012 - Conditions: HHT; Morbus Osler; Epistaxis
Interventions: Drug: Bevacizumab; Drug: NaCl
Sponsors: Medical University of Vienna; Medical University of Vienna
Recruiting - verified December 2011 - Conditions: Degenerative Joint Disease; Congenital Deformity; Arthritis; Osteoarthritis; Rheumatoid Arthritis
Interventions: Device: Augment(tm) Injectable Bone Graft; Procedure: Autologous bone graft
Sponsors: BioMimetic Therapeutics; BioMimetic Therapeutics
Recruiting - verified July 2011 - Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Carcinoma, Thymic
Interventions: Drug: AZD; Drug: MK-2206; Drug: Lapatinib; Drug: Erlotinib; Drug: Sunitinib; Procedure: Molecular Profiling
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: Rituximab; Drug: lenalidomide
Sponsors: Swiss Group for Clinical Cancer Research; Swiss Group for Clinical Cancer Research
Recruiting - verified March 2012 - Condition: X-linked Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: University Hospital Erlangen; University Hospital Erlangen; Edimer Pharmaceuticals
Recruiting - verified September 2011 - Condition: OCD
Intervention:
Sponsors: Kunming Medical College; Kunming Medical College
Recruiting - verified September 2011 - Conditions: Burns; Growth Factors, Combined Defect of; Inflammation; Cytokine Storm
Intervention:
Sponsors: Federal University of São Paulo; Federal University of São Paulo
Recruiting - verified January 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Secondary Acute Myeloid Leukemia
Interventions: Radiation: Indium-111 111In anti-CD45 monoclonal antibody BC8 (dosimetric dose); yttrium Y 90 anti-CD45 monoclonal antibody BC8 (therapeutic dose); Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: flow cytometry; Genetic: cytogenetic analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Genetics; Genetic Disease; Genetic Linkage; Birth Defects; Genetic Variation
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011 - Condition: Postural Tachycardia Syndrome
Interventions: Behavioral: Seated Measurements; Behavioral: Standing Measurements; Behavioral: Self-Administered Surveys
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Cirrhosis
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified December 2011 - Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: bendamustine; Drug: cyclophosphamide; Drug: Fludarabine; Drug: RO5072759
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Solid Cancers
Intervention: Drug: GDC-0032
Sponsors: Genentech; Genentech
Recruiting - verified January 2012 - Condition: Intensive Care Unit Syndrome
Interventions: Other: Measure of intravesical pressure; Other: Measure of intravesical pressure
Sponsors: Rennes University Hospital; Rennes University Hospital
Recruiting - verified November 2011 - Condition: Lymphangioma
Intervention: Drug: Sildenafil
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012 - Condition: Cancer
Interventions: Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: fertility assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Institut Catala D'Oncologia
Recruiting - verified February 2011 - Conditions: Coronary Artery Disease; Anesthesia, General; Coronary Artery Bypass Graft Surgery
Interventions: Drug: Xenon; Drug: Sevoflurane; Drug: Propofol
Sponsors: Air Liquide Santé International; Air Liquide Santé International
Recruiting - verified March 2012 - Conditions: Insulin Resistance; Obesity
Interventions: Behavioral: weight loss; Behavioral: weight maintenance
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified August 2011 - Condition: Advanced Solid Tumors
Interventions: Drug: Ombrabulin (AVE8062); Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Tumors Characterized by Genetic Abnormalities of ALK
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Patent Ductus Arteriosus
Interventions: Drug: Paracetamol; Drug: NSAID; Drug: D5W
Sponsors: Shaare Zedek Medical Center; Shaare Zedek Medical Center
Not yet recruiting - verified February 2011 - Conditions: DNA Damage; Other Complications Associated With Artificial Fertilization
Intervention:
Sponsors: University of South Florida; University of South Florida
Recruiting - verified November 2011 - Conditions: Fungal Infection; Leukemia; Myelodysplastic Syndromes
Intervention: Drug: caspofungin acetate
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified May 2012 - Condition: All Indications for Glivec/Gleevec and Tasigna
Intervention: Drug: Tasigna, Gleevec
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Schistosomiasis [Bilharziasis]
Intervention: Drug: Praziquantel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 2011 - Condition: Multiple Sclerosis
Intervention: Drug: fingolimod
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Tuberous Sclerosis Complex
Intervention: Drug: RAD001
Sponsors: Children's Hospital Boston; Mustafa Sahin; Tuberous Sclerosis Alliance; Autism Speaks; Novartis Pharmaceuticals; Seizure Tracker LLC
Recruiting - verified February 2012 - Condition: DLBCL
Intervention:
Sponsors: Rennes University Hospital; Rennes University Hospital; Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS; National Cancer Institute, France
Recruiting - verified February 2012 - Condition: Severe Facial Deformity
Intervention: Procedure: Facial Allograft Transplantation
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Department of Defense
Recruiting - verified July 2011 - Conditions: Hypogonadotropic Hypogonadism; Kallmann Syndrome
Interventions: Drug: Tranditional intervention for HH using HCG and FSH; Drug: Sequential intervention for HH using HCG and FSH; Drug: Sequential intervention for HH using HCG and FSH plus zinc
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine
Recruiting - verified December 2010 - Conditions: Infection; Cancer; Neoplasm; Empyema; Granuloma
Interventions: Device: Xperguide CT; Device: Electromagnetic Tracking; Device: Computed Tomography
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified September 2011 - Condition: Breast Reconstruction
Interventions: Device: Mentor Becker 25 Expander/Breast Implant; Device: Mentor Becker 50 Expander/Breast Implant
Sponsors: Mentor Worldwide, LLC; Mentor Worldwide, LLC
Recruiting - verified March 2012 - Condition: Lung Cancer, Small Cell
Interventions: Drug: pazopanib; Drug: pemetrexed
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Congenital Heart Defects
Interventions: Behavioral: Clinic-based Educational Intervention; Other: Usual Care
Sponsors: University of Alberta; University of Alberta; Women and Children's Health Research Institute, Canada; Stollery Children's Hospital Foundation
Recruiting - verified January 2012 - Conditions: Caridovascular Disease; Congenital Heart Disease; Pulmonary Hypertension
Interventions: Device: Balloon catheter for right heart catheterization; Drug: Gadopentate Dimeglumine (Gadolinium); Contrast Agent; Procedure: Right Heart Catheterization; Procedure: Cardiac Real-time MRI; Procedure: Vascular Hemostasis
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011 - Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
Sponsors: Great Ormond Street Hospital for Children NHS Trust; Great Ormond Street Hospital for Children NHS Trust
Recruiting - verified March 2012 - Condition: HIV Infection Associated Kaposi Disease
Intervention: Drug: Lenalidomide
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis; Celgene Corporation
Recruiting - verified June 2011 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Influenza; Pneumonia, Viral; Pulmonary Fibrosis; Quality of Life; Stress Disorders, Post Traumatic
Intervention:
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified January 2012 - Condition: Severe Facial Deformities
Intervention: Procedure: Surgical Procedure Composite Facial Transplant
Sponsors: The Cleveland Clinic; The Cleveland Clinic; Department of Defense
Recruiting - verified February 2012 - Conditions: Epilepsy; Epilepsy, Temporal Lobe; Partial Epilepsy
Intervention: Procedure: Surgery
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2011 - Conditions: Aortic Stenosis; LV Remodeling, Hypertrophy
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified August 2011 - Condition: Aortic Stenosis
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified August 2011 - Condition: Airway Hyperreactivity and Lower Respiratory Morbidity After Palivizumab in Premature Babies (30-32 Weeks)
Interventions: Other: Methacholine Challenge Test (MCT); Other: Exhaled breath condensate (EBC); Other: Monthly telephone contact; Other: Visits to the study site; Other: Allergic Skin Test; Other: Blood Test
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Not yet recruiting - verified December 2010 - Condition: Melanoma
Interventions: Drug: Timolol + LCP; Device: LCP
Sponsors: Centre Hospitalier Universitaire de Nice; Centre Hospitalier Universitaire de Nice
Recruiting - verified January 2011 - Condition: Vertebral Body Augmentation
Intervention: Procedure: robotic assisted surgery
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified August 2011 - Condition: AML
Intervention:
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Recruiting - verified June 2011 - Condition: Complex Partial Seizures
Intervention: Drug: vigabatrin
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified November 2011 - Conditions: Gulf War Syndrome; Mitochondrial Disease
Interventions: Procedure: Skin biopsy; Procedure: Blood Collection
Sponsors: Medical Neurogenetics, LLC; Medical Neurogenetics, LLC; Department of Defense
Recruiting - verified September 2011 - Conditions: Lower Limbs Deformities; Gait; Energy Expenditure
Intervention:
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Recruiting - verified July 2011 - Condition: Autism Spectrum Disorders
Interventions: Drug: Intranasal Oxytocin; Drug: Placebo
Sponsors: Montefiore Medical Center; Montefiore Medical Center; National Alliance for Research on Schizophrenia and Depression
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention:
Sponsors: Kunming Medical College; Kunming Medical College; Chinese Academy of Sciences
Recruiting - verified June 2011 - Condition: Atherosclerosis
Interventions: Drug: MLDL1278A; Drug: MLDL1278A; Drug: placebo; Drug: statin, stable dose
Sponsors: Genentech; Genentech; BioInvent International AB
Recruiting - verified February 2012 - Conditions: Craniofacial Abnormalities; Cleft Lip; Cleft Palate
Intervention:
Sponsors: University of Iowa; University of Iowa; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified November 2011 - Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Hydroxyurea; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified December 2011 - Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome; Cardiovascular Disease
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Recruiting - verified October 2011 - Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: clofarabine; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Genetic: fluorescence in situ hybridization; Procedure: peripheral blood stem cell transplantation; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: HIV
Interventions: Drug: Single-dose nevirapine; Drug: Zidovudine; Drug: Infant dose nevirapine; Drug: Emtricitabine/tenofovir disoproxil fumarate fixed-dose combination; Drug: Zidovudine/lamivudine fixed dose combination; Drug: Lopinavir/ritonavir fixed dose combination
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: sorafenib tosylate; Genetic: cytogenetic analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Pneumococcal Disease; Haemophilus Influenzae Infections
Interventions: Biological: Pneumococcal vaccine GSK2189242A (formulation 1); Other: Pneumococcal vaccine GSK2189242A (formulation 2); Biological: SynflorixTM; Biological: Prevenar 13TM; Biological: TritanrixTM-HepB/Hib; Biological: Polio SabinTM; Biological: M-VacTM; Biological: StamarilTM
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Program for Appropriate Technology in Health; Department of State for Health and Social Welfare, The Gambia; Medical Research Council Laboratories, Gambia; London School of Hygiene and Tropical Medicine
Recruiting - verified December 2011 - Condition: Rett Syndrome
Intervention: Drug: rhIGF-1
Sponsors: Children's Hospital Boston; Scott Pomeroy; International Rett Syndrome Foundation; Autism Speaks
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University of Arkansas; University of Arkansas; National Institutes of Health (NIH)
Recruiting - verified March 2012 - Conditions: Wound Infection; Abscess; Systemic Inflammation; Cellulitis
Interventions: Drug: Single-Dose IV Oritavancin Diphosphate; Drug: IV Vancomycin
Sponsors: The Medicines Company; The Medicines Company
Recruiting - verified February 2012 - Conditions: Wound Infection; Abscess; Systemic Inflammation; Cellulitis
Interventions: Drug: Single-Dose IV Oritavancin Diphosphate; Drug: IV Vancomycin
Sponsors: The Medicines Company; The Medicines Company
Recruiting - verified February 2012 - Conditions: Ovarian Diseases; Ovarian Neoplasms
Interventions: Other: Laboratory Tumor Marker Analysis; Other: Transvaginal Ultrasound; Other: Health Status Questionnaire
Sponsors: Swedish Medical Center; Swedish Medical Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research
Recruiting - verified May 2012 - Conditions: Cerebral Palsy; Muscle Spasticity; Children
Interventions: Drug: Botulinum type A toxin (Dysport®); Drug: Placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified March 2012 - Conditions: Cerebral Palsy; Muscle Spasticity; Children
Intervention: Drug: Botulinum type A toxin (Dysport®)
Sponsors: Ipsen; Ipsen
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: azacitidine; Drug: cytarabine; Drug: etoposide phosphate; Drug: mitoxantrone hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Use of Atypical Antipsychotics During Pregnancy
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; AstraZeneca; Bristol-Myers Squibb; Ortho-McNeil Janssen Scientific Affairs, LLC; Pfizer
Recruiting - verified July 2011 - Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy
Intervention: Drug: Ataluren
Sponsors: PTC Therapeutics; PTC Therapeutics; Genzyme
Recruiting - verified August 2011 - Condition: Autism Spectrum Disorders
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Mclean Hospital
Recruiting - verified December 2011 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: lenalidomide
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Condition: Psoriasis
Interventions: Drug: CP 690,550 5 mg; Drug: CP 690,550 10 mg; Biological: Etanercept 50 mg; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Congenital Diaphragmatic Hernia; Congenital Diaphragmatic Eventration; Congenital Hiatal Hernia; Congenital Diaphragmatic Disorders
Intervention:
Sponsors: University of Utah; University of Utah
Recruiting - verified May 2012 - Conditions: Ankle Equinus; Ankle Contracture; Diabetes Mellitus
Interventions: Other: Standard of care; Device: Dynasplint
Sponsors: Dynasplint Systems, Inc.; Dynasplint Systems, Inc.
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Intervention: Other: computer-assisted intervention
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Cytarabine; Drug: Etoposide; Drug: All-trans retinoic acid (ATRA)
Sponsors: University of Ulm; University of Ulm; German Federal Ministry of Education and Research
Recruiting - verified February 2012 - Condition: HIV-1 Infection
Interventions: Drug: atorvastatin; Drug: atorvastatin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer
Recruiting - verified September 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Graft Versus Host Disease; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: palifermin; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Kidney Diseases
Interventions: Dietary Supplement: Control; Dietary Supplement: Protein; Other: Protein + Exercise
Sponsors: University of Illinois at Urbana-Champaign; University of Illinois at Urbana-Champaign; University of Illinois
Recruiting - verified June 2011 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Other: Early hospital discharge; Other: Medical chart review; Other: Questionnaire administration; Other: Electronic billing information review
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center
Recruiting - verified February 2012 - Conditions: Advanced Solid Tumor; Lymphomas
Intervention: Drug: LEE011
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hepatocellular Carcinoma
Intervention: Device: transarterial chemoembolization using a drug-eluting bead
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012 - Condition: Pregnancy Complicated by Malaria as Antepartum Condition
Interventions: Drug: artesunate-amodiaquine; Drug: Dihydroartemisinin-piperaquine
Sponsors: Kwame Nkrumah University of Science and Technology; Kwame Nkrumah University of Science and Technology
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Anemia With Excess Blasts; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenström Macroglobulinemia
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: sirolimus; Drug: mycophenolate mofetil; Other: flow cytometry; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Oligospermia
Intervention: Other: methylation analyses on spermatozoa from infertile men
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified July 2011 - Conditions: Influenza A Virus, H1N1 Subtype; Influenza, Human; Influenza B Virus; Influenza, Seasonal
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Patients With Primary Hyperparathyroidism (PHPT)
Intervention:
Sponsors: Postgraduate Institute of Medical Education and Research; Postgraduate Institute of Medical Education and Research
Recruiting - verified June 2011 - Condition: Actinic Keratosis
Interventions: Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm; Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Sponsors: Frankel, Amylynne, M.D.; Frankel, Amylynne, M.D.; Graceway Pharmaceuticals, LLC
Recruiting - verified June 2011 - Condition: Spinal Deformity
Intervention: Procedure: Surgery
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012 - Condition: Congenital Malformations
Interventions: Drug: folic acid; Drug: folic acid
Sponsors: Azienda Ospedaliera Universitaria Integrata Verona; Azienda Ospedaliera Universitaria Integrata Verona; International Centre of Birth Defects
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011 - Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: CC-11050
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012 - Conditions: Congenital Heart Disease; Cardiopulmonary Bypass
Intervention: Drug: Acetaminophen
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified April 2012 - Condition: Renal Transplant
Interventions: Drug: Telmisartan; Drug: Losartan
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research
Recruiting - verified June 2011 - Condition: Acute Myeloid Leukemia (AML)
Intervention: Drug: Panobinostat
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Heart Septal Defects, Atrial
Interventions: Drug: Bosentan; Drug: Placebo
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified October 2010 - Conditions: Plagiocephaly; Scaphocephaly; Brachycephaly
Intervention: Device: cranial cup device
Sponsors: Children's Hospital Boston; Children's Hospital Boston; Boston Brace
Recruiting - verified June 2011 - Condition: Diabetes Mellitus
Interventions: Other: Diet; Other: No intervention
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; Istituto Superiore di Sanita
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Lymphatic Malformations
Intervention: Drug: Selenium
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin
Recruiting - verified June 2011 - Conditions: Complete DiGeorge Anomaly; DiGeorge Syndrome; DiGeorge Anomaly; Complete DiGeorge Syndrome
Interventions: Biological: Thymus Transplantation; Procedure: Blood Draw
Sponsors: Duke University; M. Louise Markert; National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Cardiac Surgical Procedures
Intervention:
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Hypoplastic Left Heart Syndrome
Intervention: Device: Peritoneal dialysis
Sponsors: University of Alberta; University of Alberta; Women and Children's Health Research Institute, Canada
Recruiting - verified May 2012 - Condition: Pregnancy Outcome
Intervention:
Sponsors: Microbicide Trials Network; Microbicide Trials Network; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institutes of Health (NIH); Gilead Sciences; CONRAD
Recruiting - verified August 2011 - Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Merck; Gilead Sciences
Recruiting - verified February 2012 - Condition: Subjects Suffering of Lateralized Lumbago on Side of the Malformation (Neo-articulation)
Interventions: Drug: corticoid (altim® 1.5 ml); Drug: physiological solution (1.5 ml)
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified September 2010 - Conditions: Recent Stroke; Pulmonary Embolism; Patent Foramen Ovale
Intervention:
Sponsors: University Hospital, Brest; University Hospital, Brest
Recruiting - verified December 2011 - Conditions: CCSVI; Chronic Cerebrospinal Venous Insufficiency; Venous Malformations of CNS Draining Veins
Intervention: Procedure: venous angioplasty
Sponsors: Hubbard Foundation; Hubbard Foundation
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Hepatitis B Virus
Interventions: Drug: pegIFN; Drug: pegIFNα-2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Cardiovascular Diseases
Intervention:
Sponsors: Abbott; Abbott; QUASY
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis; Cytopenias; White Blood Cell Abnormalities; Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified June 2011 - Conditions: HIV Infection; Young Adult
Intervention: Biological: blood sampling, specific biological exams and biobank and self administered questionnaires
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis; Pr Boccara Service Cardiologie Hôpital St Antoine PARIS; Dr Vigouroux Fac PM Curie Inserm U938 PARIS; Dr Carlier Service Radiologie Imagerie Médicale Hôpital Raymond Poincarré GARCHES; Dr Kolta Service Rhumatologie Hôpital Cochin PARIS; Dr Appay Immunologie Inserm U945 Hôpital Pitié Salpétrière PARIS; Pr Rouzioux Virologie, Bactériologie Hôpital Necker PARIS; Dr Treluyer CIC Necker PARIS
Recruiting - verified August 2011 - Conditions: Hematopoietic/Lymphoid Cancer; Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Cytomegalovirus Infection; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: infection prophylaxis and management; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: DNA analysis; Genetic: RNA analysis; Procedure: management of therapy complications; Drug: ganciclovir; Drug: valganciclovir; Drug: foscarnet sodium; Procedure: antiviral therapy; Genetic: polymerase chain reaction; Genetic: protein expression analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Lung Cancer
Intervention: Procedure: intracavitary ultrasound
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM)
Recruiting - verified November 2011 - Condition: Anaplastic Glioma
Intervention: Other: 18F-FMISO PET-scanning
Sponsors: University Hospital, Caen; University Hospital, Caen
Recruiting - verified March 2012 - Conditions: Obesity; Type 2 Diabetes
Intervention:
Sponsors: CPL Associates; CPL Associates; VascuFlo Inc.
Recruiting - verified June 2011 - Condition: Congenital Heart Disease
Intervention: Other: Blood Sample Collection
Sponsors: Nationwide Children's Hospital; Nationwide Children's Hospital
Recruiting - verified February 2012 - Condition: Congenital Heart Defects
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Intervention: Procedure: Whole-body Cooling
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2012 - Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified November 2011 - Conditions: Human Papillomavirus Infection; Cervical Neoplasia
Interventions: Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Fragile X Syndrome; FMR1 Premutation; Primary Ovairan Insufficiency; Premature Ovarian Failure; Premature Menopause
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Blood Component Transfusion; Cardiac Surgical Procedures
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Blood Services; Canadian Institutes of Health Research (CIHR)
Recruiting - verified October 2011 - Condition: Postural Tachycardia Syndrome
Interventions: Drug: Losartan; Drug: Ascorbic Acid (Vitamin C); Drug: Normal Saline
Sponsors: New York Medical College; New York Medical College
Recruiting - verified December 2011 - Condition: Femoroacetabular Impingement
Interventions: Procedure: MRI, qCT, motion analysis; Procedure: MRI, qCT, motion analysis; Procedure: MRI, qCT, motion analysis
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2012 - Conditions: Dyslipidemias; Hypercholesterolemia; Hypertriglyceridemia; High LDL-C; Low HDL-C
Interventions: Drug: Statin; Drug: Statin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Procedure: umbilical cord blood transplantation; Drug: fludarabine phosphate; Drug: cyclophosphamide; Procedure: ex vivo-expanded cord blood progenitor cell infusion; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Congenital Heart Disease
Intervention: Drug: Bosentan
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Berto J Bouma
Recruiting - verified September 2011 - Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following; Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
Interventions: Drug: midostaurin, bortezomib,; Drug: mitoxantrone hydrochloride, etoposide, cytarabine, midostaurin, bortezomib
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Novartis; Millennium Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Conditions: Rheumatic Heart Disease; Congenital Heart Disease; Aneurysm; Heart Valve Disease
Intervention: Drug: Simvastatin
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Recruiting - verified September 2010 - Condition: AML
Intervention: Drug: Lenalidomide
Sponsors: PETHEMA Foundation; PETHEMA Foundation
Recruiting - verified January 2012 - Condition: Copper Deficiency
Intervention: Dietary Supplement: Copper gluconate
Sponsors: Emory University; Emory University
Recruiting - verified July 2010 - Condition: Type 2 Diabetes
Intervention: Other: Diagnostic
Sponsors: Norwegian University of Science and Technology; Norwegian University of Science and Technology; Volda Hospital
Recruiting - verified December 2011 - Condition: Obesity, Morbid
Interventions: Procedure: laparoscopic adjustable gastric band; Behavioral: Combined life style interventions
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Recruiting - verified October 2011 - Condition: Chronic Obstructive Pulmonary Disease
Intervention: Dietary Supplement: Essential amino acid intake + Leucine vs total AA supplement
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Condition: Maternal Depression
Intervention: Behavioral: Project Solve Education
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified June 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Dietary Supplement: EAA+LEU vs total AA; Dietary Supplement: Total AA vs EAA+LEU
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: azacitidine; Drug: busulfan; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy
Intervention: Drug: Sildenafil
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Johns Hopkins University
Recruiting - verified April 2012 - Condition: Fabry Disease
Intervention: Other: Fluorescein angiography
Sponsors: Ohio State University; Ohio State University; Genzyme
Recruiting - verified August 2011 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Mature T-cell and Nk-cell Neoplasms; Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: nelfinavir mesylate
Sponsors: Swiss Group for Clinical Cancer Research; Swiss Group for Clinical Cancer Research
Recruiting - verified April 2012 - Condition: Hereditary Hemorrhagic Telangiectasia
Intervention:
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Other: enzyme-linked immunosorbent assay; Genetic: microarray analysis; Other: questionnaire administration; Other: preventative dietary intervention
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Tasocitinib plus Methotrexate; Drug: Tasocitinib plus placebo methotrexate; Drug: Placebo tasocitinib plus Methotrexate
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Persistent Corneal Epithelial Defects
Interventions: Drug: Nexagon; Drug: Vehicle only
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified November 2011 - Conditions: Atopic Dermatitis; Netheron's Syndrome; Piebaldism; Hyper IgE Syndrome; Ichthyosis; Anaphylaxis; Severe Allergy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Haemodialysis
Intervention: Other: Use of ultrasound guidance in cannulation
Sponsors: University of Hull; University of Hull
Not yet recruiting - verified July 2010 - Conditions: Pulmonary Arterial Hypertension; HIV Infection; Congenital Heart Defect; Systemic Sclerosis; Connective Tissue Disease
Interventions: Procedure: skin biopsy; Other: Blood Sample
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Conditions: High Mammographic Density; Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Vertigo; Headache; Anomaly of Vergence System; Accommodation Disorders; Orthoptic Rehabilitation
Interventions: Procedure: orthoptic rehabilitation; Other: Orthoptic diagnostic
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; France: Centre National de la Recherche Scientifique
Recruiting - verified May 2010 - Conditions: Syringomyelia; Arnold Chiari Deformity
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Condition: Non-24-Hour Sleep-Wake Disorder
Interventions: Drug: tasimelteon; Drug: Placebo
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Drug: cytarabine; Drug: etoposide; Drug: everolimus; Drug: idarubicin; Drug: mitoxantrone hydrochloride
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Conditions: Failing Fontan Physiology; Failing Fontan; Single-ventricle; Single-ventricle Fontan; Single-ventricle Physiology
Intervention: Device: HeartMate II Ventricular Assist Device
Sponsors: Providence Health & Services; Timothy Icenogle, MD; Alexa Schmitt, PhD
Recruiting - verified March 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: PCOS
Interventions: Drug: Dexamethasone and recombinant hCG; Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
Sponsors: University of California, San Diego; University of California, San Diego; University of Virginia
Recruiting - verified August 2011 - Condition: Anesthesia
Interventions: Drug: Lidocaine; Drug: Placebo
Sponsors: Hopital Foch; Hopital Foch
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Intervention: Device: Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2011 - Conditions: Stroke; Foramen Ovale, Patent
Intervention:
Sponsors: University Hospital, Geneva; University Hospital, Geneva
Recruiting - verified August 2011 - Conditions: Hypersomnia; Idiopathic Hypersomnia; Narcolepsy
Interventions: Drug: Clarithromycin followed by placebo; Drug: Placebo then Clarithromycin
Sponsors: Emory University; Lynn Marie Trotti
Recruiting - verified March 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bendamustine hydrochloride; Drug: idarubicin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Wounds
Interventions: Device: 2-octylcyanoacrylate (Dermabond) closure; Device: Standard staple closure
Sponsors: University of British Columbia; University of British Columbia; BCCH Telethon Grant
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: temozolomide; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Hydronephrosis; Urinary Tract Infection
Interventions: Drug: Trimethoprim; Other: Simple Syrup
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified July 2011 - Condition: Glioma
Intervention: Drug: nilotinib
Sponsors: University of California, San Diego; University of California, San Diego; Novartis
Recruiting - verified January 2012 - Condition: Dystonic Cerebral Palsy
Interventions: Drug: L- DOPA; Drug: placebo
Sponsors: Shaare Zedek Medical Center; Shaare Zedek Medical Center
Recruiting - verified May 2011 - Condition: Coronary Vessel Anomalies
Intervention: Procedure: revascularization
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified July 2011 - Conditions: Chronic Myeloproliferative Disorders; Cognitive/Functional Effects; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure; Other: cytology specimen collection procedure
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: Tenofovir 1% gel; Other: Placebo gel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: Spinal Fusion; Antifibrinolytic Agents; Hemorrhage; Blood Transfusion
Interventions: Drug: Tranexamic Acid; Drug: fisiologic serum
Sponsors: Hospital Universitari Vall d'Hebron Research Institute; Hospital Universitari Vall d'Hebron Research Institute; Hospital Vall d'Hebron; Hospital Clinic of Barcelona; Hospital Universitari de Bellvitge; Hospital Universitario Getafe
Recruiting - verified March 2012 - Condition: Hypertension
Intervention:
Sponsors: Columbia University; Columbia University; Mount Sinai School of Medicine; Weill Medical College of Cornell University
Recruiting - verified February 2012 - Conditions: Pregnancy; Congenital Defects; Infant, Low Birth Weight
Intervention: Drug: telavancin
Sponsors: Theravance; Theravance
Recruiting - verified April 2012 - Condition: Congenital Glaucoma
Intervention:
Sponsors: Carmel Medical Center; Carmel Medical Center
Recruiting - verified June 2011 - Condition: Congenital Heart Disease
Intervention:
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia
Recruiting - verified December 2011 - Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaConditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: bortezomib; Drug: mitoxantrone hydrochloride; Drug: etoposide; Drug: cytarabine; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified April 2012 - Condition: Liver Transplantation
Interventions: Drug: MMF(1000mg bid) + tacrolimus + standard of care medications; Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications; Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications; Drug: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Fibromyalgia
Interventions: Drug: Duloxetine; Procedure: Skin biopsy
Sponsors: Albany Medical College; Albany Medical College
Recruiting - verified December 2010 - Condition: Fibromyalgia
Interventions: Drug: Milnacipran; Procedure: Skin biopsy
Sponsors: Albany Medical College; Albany Medical College; Forest Laboratories
Recruiting - verified December 2010 - Conditions: Congenital Heart Disease; Prematurity; Necrotizing Enterocolitis
Intervention:
Sponsors: University of Utah; University of Utah
Recruiting - verified May 2012 - Condition: Neoplasms Malignant
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: management of therapy complications; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Atrial Septal Defect; Ventricular Septal Defect; Atrioventricular Septal Defect
Interventions: Drug: Intravenous L-Citrulline; Drug: Placebo of Intravenous L-Citrulline
Sponsors: Asklepion Pharmaceuticals, LLC; Asklepion Pharmaceuticals, LLC
Recruiting - verified September 2011 - Condition: Abnormality
Intervention: Procedure: skin biopsy
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Research Institute
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified May 2012 - Condition: Helicobacter Pylori Infection
Intervention: Drug: GT08
Sponsors: Synergy Pharmaceuticals Pte. Ltd.; Synergy Pharmaceuticals Pte. Ltd.; Singapore General Hospital
Recruiting - verified May 2011 - Conditions: ADHD; Growth
Interventions: Behavioral: behavioral therapy; Drug: 12 hour methylphenidate product; Behavioral: increased monitoring of growth; Drug: drug holiday; Dietary Supplement: caloric supplement
Sponsors: Florida International University; Florida International University
Recruiting - verified March 2012 - Conditions: Diffuse Intrinsic Pontine Glioma; Brainstem Glioma
Intervention:
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia; Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: Biological: filgrastim; Drug: clofarabine; Drug: cytarabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Intervention:
Sponsors: Columbia University; Columbia University; Mayo Clinic
Recruiting - verified February 2012 - Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit; Drug: Etoposide; Drug: Intrathecal Methotrexate; Drug: hydrocortisone
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012 - Conditions: Osteoarthritis; Arthritis; Avascular Necrosis; Fracture of the Femoral Neck or Head; Congenital Hip Dysplasia
Intervention: Device: AMIStem Hip System
Sponsors: Medacta International SA; Medacta International SA
Recruiting - verified January 2012 - Conditions: Stage 2-5 Chronic Kidney Disease; Predialysis
Intervention:
Sponsors: National University, Singapore; National University, Singapore; National Kidney Foundation, Singapore
Recruiting - verified May 2012 - Conditions: Pregnancy; Fetal and Neonatal Health
Intervention:
Sponsors: University of Luebeck; University of Luebeck
Recruiting - verified August 2011 - Condition: Intermittent Preventive Treatment In Pregnancy (IPTp)
Interventions: Drug: Azithromycin plus chloroquine; Drug: sulfadoxine-pyrimethamine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: ADHD
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified February 2012 - Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Drug: Asimadoline; Drug: Placebo
Sponsors: Tioga Pharmaceuticals; Tioga Pharmaceuticals; RTI Health Solutions
Recruiting - verified March 2012 - Conditions: Birth Defects; Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Cervical Cancer; Precancerous Condition
Intervention: Device: Multispectral Digital Colposcope (MDC)
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; National Cancer Institute (NCI)
Not yet recruiting - verified July 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Trinitrin; Drug: Neosynephrine 10% collyrium; Drug: Iontophoresis with acetylcholine delivery; Device: Dynamic Vessel Analyzer
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2011 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: ABT-348; Drug: ABT-348 and carboplatin; Drug: ABT-348 and docetaxel; Drug: ABT-348; Drug: ABT-348
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Myelodysplasia
Interventions: Drug: ABT-348; Drug: ABT-348; Drug: ABT-348 and azacitidine
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Melphalan, Prednisone, Lenalidomide; Drug: Cyclophosphamide, Prednisone, Lenalidomide; Drug: Lenalidomide, dexamethasone
Sponsors: Fondazione Neoplasie Sangue Onlus; Fondazione Neoplasie Sangue Onlus
Recruiting - verified December 2011 - Condition: Melanoma
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012 - Conditions: Skeletal Deformities; Leg Length Discrepancy
Intervention: Dietary Supplement: gastrolith calcium
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization; Amorfical
Recruiting - verified December 2011 - Conditions: Autism; Tuberous Sclerosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011 - Condition: Obesity
Intervention: Dietary Supplement: meal replacements, psychotherapy, dietary education
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institutes of Health (NIH)
Recruiting - verified October 2011 - Conditions: Multiple Congenital Anomaly Syndromes; Congenital Disorders; Inherited Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2011 - Conditions: Crohn's Disease; Rheumatoid Arthritis
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; The Organization of Teratology Information Specialists; Abbott
Recruiting - verified April 2012 - Condition: Intestinal Abnormalities
Intervention: Device: PillCam SB2
Sponsors: Given Imaging Ltd.; Given Imaging Ltd.
Recruiting - verified November 2011 - Condition: Stages II-III Breast Cancer
Interventions: Drug: Nanoparticle Albumin Bound Paclitaxel; Drug: doxorubicin; Drug: cyclophosphamide
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011 - Conditions: Type 1 Diabetes; Type 2 Diabetes
Interventions: Radiation: Radiography; Other: Urine and Blood sampling; Other: Echography
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified January 2012 - Conditions: Prostate Cancer; Erectile Dysfunction
Intervention: Biological: injection of bone marrow mononucleated cells
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2011 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Parkinson's Disease
Intervention:
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified January 2012 - Conditions: Parkinson's Disease; MRI
Intervention: Other: 3T and 7T MR imaging
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified January 2012 - Condition: Infant, Premature, Diseases
Intervention: Behavioral: Enhanced Discharge process
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified June 2011 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide
Sponsors: Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; ClinAssess - Gesellschaft für klinische Forschung mbH
Recruiting - verified July 2010 - Condition: Thrombosis
Intervention: Drug: Low molecular weight heparin
Sponsors: Third Military Medical University; Third Military Medical University; Chongqing Medical University
Recruiting - verified January 2012 - Conditions: Obstructive Sleep Apnea; Obesity
Interventions: Procedure: Bariatric surgery; Device: Continuous positive airway pressure
Sponsors: Kuopio University Hospital; Kuopio University Hospital; Helsinki University Central Hospital; Turku University Hospital; Oulu University Hospital; Vaasa Central Hospital, Vaasa, Finland; National Institute for Health and Welfare, Finland; Helsingin Uniklinikka; Central Hospital of Kanta-Hame
Recruiting - verified May 2012 - Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: palivizumab (Synagis)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Pregnancy
Intervention: Drug: duloxetine
Sponsors: Eli Lilly and Company; Eli Lilly and Company; INC Research, LLC
Recruiting - verified February 2012 - Conditions: Rheumatoid Arthritis; Osteoarthritis; Post-traumatic Arthritis; Avascular Necrosis; Traumatic Femoral Fractures; Congenital Hip Dysplasia
Intervention: Device: DePuy Proxima™ Hip
Sponsors: DePuy International; DePuy International
Recruiting - verified February 2012 - Condition: Cardiac Diseases
Intervention:
Sponsors: University Hospital, Toulouse; University Hospital, Toulouse
Recruiting - verified October 2011 - Conditions: Cancer Survivor; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Testicular Germ Cell Tumor
Interventions: Genetic: DNA analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Vanderbilt University; Vanderbilt University; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); University of Arizona
Recruiting - verified October 2011 - Condition: Infertility
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Institut National de la Santé Et de la Recherche Médicale, France; University Paris 7 - Denis Diderot
Recruiting - verified December 2011 - Conditions: Ischemic Cardiomyopathy; Nonischemic Cardiomyopathy
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; Donald W. Reynolds Foundation; Christiana Care Health Services
Recruiting - verified June 2011 - Conditions: Metastatic Renal Cell Carcinoma; Gastrointestinal Stromal Tumors
Intervention: Drug: Sunitinib malate
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Pregnancy
Intervention:
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke
Recruiting - verified March 2012 - Condition: Thrombosis
Interventions: Drug: Variation of heparin dose; Drug: Variation of heparin dose
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM)
Recruiting - verified April 2012 - Condition: Chiari Type I Malformation
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified June 2011 - Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Eltrombopag
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Migraine Disorders
Interventions: Drug: Sumatriptan; Drug: Naratriptan; Drug: Sumatriptan-naproxen combination
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: HIV Infections
Interventions: Drug: Zidovudine (ZDV); Drug: Nevirapine (NVP); Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Drug: Lamivudine-Zidovudine (3TC-ZDV); Drug: Lopinavir-ritonavir (LPV-RTV); Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Drug: Nevirapine (NVP); Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Drug: Lopinavir/ritonavir (LPV-RTV); Drug: Nevirapine (NVP); Drug: Lopinavir-ritonavir (LPV-RTV); Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Drug: Cotrimoxazole (CTX); Drug: Placebo CTX
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Primary Ciliary Dyskinesia
Intervention:
Sponsors: Ziv Hospital; Ziv Hospital; Rambam Health Care Campus; Hadassah Medical Organization; Tel-Aviv Sourasky Medical Center; Sheba Medical Center; Assaf-Harofeh Medical Center; The Nazareth Hospital, Israel; Soroka University Medical Center; Shaare Zedek Medical Center; Schneider Children's Medical Center, Israel
Recruiting - verified May 2012 - Condition: Coronary Artery Bypass Graft Surgery
Intervention: Procedure: bypass graft angiography
Sponsors: North Texas Veterans Healthcare System; North Texas Veterans Healthcare System
Recruiting - verified July 2011 - Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis
Intervention: Drug: anti-TNF therapy (etanercept or adalimumab)
Sponsors: Imperial College London; Imperial College London
Recruiting - verified September 2011 - Conditions: Cervical Cancer; Cervical Intraepithelial Neoplasia
Intervention: Procedure: HPV-cytology co-testing
Sponsors: The University of Hong Kong; The University of Hong Kong; The Family Planning Association of Hong Kong
Recruiting - verified May 2011 - Condition: Malaria
Interventions: Drug: dihydroartemisinin-piperaquine; Drug: Artesunate-mefloquine; Drug: arthemeter-lumefantrin
Sponsors: University of Oxford; University of Oxford
Recruiting - verified March 2012 - Condition: Chronic Kidney Disease
Interventions: Other: Post operative progressive handgrip exercise; Other: Treatment as usual
Sponsors: Bangor University; Bangor University; Betsi Cadwaladr University Health Board
Recruiting - verified November 2011 - Condition: Heart Failure
Interventions: Behavioral: bicycle ergometer; Other: control
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Recruiting - verified October 2011 - Condition: Influenza A
Interventions: Biological: Anti-Influenza Plasma; Behavioral: Standard Care
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Procedure: Aspirin ingestion followed by doing a Bleeding Volume Test; Procedure: Gatorade Placebo followed by Bleeding Volume Test.
Sponsors: Klein, Jeffrey A., M.D.; Klein, Jeffrey A., M.D.
Recruiting - verified June 2011 - Condition: Mature B-Cell Lymphoma
Interventions: Drug: COPAD; Drug: COP, COPD M3, CYM; Drug: COP, COPADM8, CYVE
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012 - Condition: Congenital Heart Disease
Intervention:
Sponsors: Children's Hospital Boston; Children's Hospital Boston
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health
Recruiting - verified December 2011 - Conditions: Acute Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Biphenotypic Leukemia; Pre-leukemic Syndromes; Monosomy 7; Bone Marrow Clonal Malformations; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia
Intervention: Other: Withdrawal of immunosuppression and donor lymphocyte infusion
Sponsors: University of California, San Francisco; University of California, San Francisco; All Children's Hospital
Recruiting - verified March 2012 - Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: filgrastim; Procedure: ex-vivo umbilical cord blood expansion; Other: DNA analysis; Procedure: bone marrow aspiration; Genetic: cytogenetic analysis; Other: flow cytometry; Other: fluorescence in situ hybridization; Other: laboratory biomarker analysis; Drug: clofarabine; Procedure: ex vivo-expanded cord blood progenitor cell infusion
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Human Papillomavirus Infection
Interventions: Biological: GSK Biologicals' HPV vaccine 580299; Biological: Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: tacrolimus; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: laboratory biomarker analysis; Procedure: flow cytometry; Radiation: total-body irradiation; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Procedure: polymerase chain reaction; Biological: filgrastim
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Fibromyalgia
Intervention:
Sponsors: INC Research; INC Research; Forest Laboratories
Recruiting - verified March 2012 - Conditions: Congenital Heart Defects; Hypoplastic Left Heart Syndrome; Aortic Coarctation
Interventions: Procedure: Deep Hypothermic Circulatory Arrest; Procedure: Antegrade Cerebral Perfusion
Sponsors: UMC Utrecht; UMC Utrecht
Recruiting - verified July 2011 - Condition: Epidermolysis Bullosa
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Anti-thymocyte globulin; Drug: Cyclosporine A; Drug: Mycophenolate mofetil; Procedure: Hematopoietic stem cell transplant; Procedure: Mesenchymal stem cell transplant; Radiation: Total body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Anemia
Interventions: Drug: Lenalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: PHACE Syndrome
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin
Recruiting - verified July 2011 - Condition: PHACE Syndrome
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin
Recruiting - verified April 2012 - Condition: Chronic Myelomonocytic Leukemia
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012 - Condition: Age Related Macular Degeneration
Intervention: Device: Foresee Home
Sponsors: Notal Vision Ltd; Notal Vision Ltd
Recruiting - verified September 2011 - Condition: Ambiguous Genitalia
Intervention:
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Diffuse and Focal Abnormalities of the Liver and Pancreas
Intervention: Device: optimize MRI sequences
Sponsors: University of Nebraska; University of Nebraska
Recruiting - verified July 2011 - Conditions: Haemodialysis; Surgery
Intervention: Procedure: Arterial and venous duplex ultrasound examination
Sponsors: University of Hull; University of Hull
Recruiting - verified May 2010 - Conditions: Degenerative Diseases of the Central Nervous System; Ocular-motor and Vestibular Diseases
Intervention:
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Condition: Klinefelter Syndrome
Intervention:
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: Irradiated haploidentical allogeneic lymphocytes; Radiation: total-body irradiation
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Acute Leukaemia
Interventions: Procedure: Blood sampling; Procedure: Bone marrow aspiration
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified August 2011 - Condition: Cleft Palate
Intervention: Procedure: primary surgery for cleft palate
Sponsors: University of Manchester; University of Manchester; University of Liverpool; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified July 2011 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia
Interventions: Biological: pretargeted radioimmunotherapy; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Other: pharmacological study; Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Diabetes Type 2; Hypertension
Interventions: Drug: acetyl-L-carnitine/statin (simvastatin); Drug: placebo
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; Sigma Tau Pharmaceuticals, Inc.
Recruiting - verified June 2011 - Condition: Port Wine Stains
Interventions: Drug: Imiquimod (Aldara); Drug: non-medicated petroleum cream
Sponsors: University of Kentucky; University of Kentucky; Graceway Pharmaceuticals, LLC
Recruiting - verified October 2011 - Condition: Unstable Lisfranc Fracture-dislocations of the Midfoot
Interventions: Procedure: Steel screw fixation of Lisfranc fracture-dislocation.; Procedure: Absorbable screw fixation of Lisfranc fracture-dislocations.
Sponsors: Rothman Institute Orthopaedics; Rothman Institute Orthopaedics
Recruiting - verified July 2011 - Conditions: Kaposiform Hemangioendotheliomas; Tufted Angioma; Capillary Venous Lymphatic Malformation; Venous Lymphatic Malformation; Microcystic Lymphatic Malformation; Mucocutaneous Lymphangiomatosis and Thrombocytopenia; Capillary Lymphatic Arterial Venous Malformations; PTEN Overgrowth Syndrome With Vascular Anomaly; Lymphangiectasia Syndromes
Intervention: Drug: sirolimus
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012 - Conditions: Ischemic Brain Injury; Stroke; Healthy Individual; Patent Foramen Ovale (PFO); Neurovascular Injury
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified July 2011 - Conditions: Pulmonary Hypertension; Neonatal Hypoxic Respiratory Failure; Persistent Pulmonary Hypertension of Newborn; Congenital Heart Defects; Acute Respiratory Distress Syndrome
Interventions: Drug: Iloprost; Drug: Placebo
Sponsors: Seattle Children's Hospital; Seattle Children's Hospital; Actelion
Recruiting - verified July 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Hydroxychloroquine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Stanford University; Yale University; University of Maryland; Genentech
Recruiting - verified April 2012 - Condition: Double Outlet Right Ventricle
Intervention: Other: Anatomic Reconstruction and Surgical Planning
Sponsors: Emory University; Emory University
Recruiting - verified May 2011 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau DiseaseConditions: Von Hippel-Lindau Disease; Hemangioblastoma; Renal Cell Carcinoma; Pheochromocytoma; Pancreatic Neuroendocrine Tumor
Intervention: Other: 89Zr bevacizumab PET scan
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen; VHL Family Alliance
Recruiting - verified April 2012 - Condition: Diabetic Retinopathy
Interventions: Behavioral: high blood pressure treatment; Behavioral: sleep apnea treatment; Behavioral: diabetic macular edema treatment
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified September 2011 - Conditions: Myelodysplastic Syndromes; Thrombocytopenia
Intervention: Drug: Eltrombopag
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2012 - Conditions: Growth Hormone Deficiency; Traumatic Brain Injury
Interventions: Drug: Human Growth Hormone; Drug: Placebo
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; The Moody Foundation
Recruiting - verified December 2011 - Condition: Bronchopulmonary Dysplasia
Interventions: Drug: Inhaled Nitric Oxide (iNO); Drug: Nitrogen (placebo)
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2012 - Condition: Congenital Diaphragmatic Hernia
Intervention:
Sponsors: Columbia University; Columbia University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Congenital Pediatric Disorders
Interventions: Drug: Busulfan; Drug: Cytoxan; Drug: Fludarabine
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified August 2011 - Condition: Myeloproliferative Neoplasms
Intervention: Drug: Pomalidomide
Sponsors: University of Ulm; University of Ulm
Recruiting - verified November 2011 - Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Metacarpal Shaft Fractures
Intervention:
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Recruiting - verified December 2011 - Condition: Systemic Capillary Leak Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: 3'-deoxy-3'-[18F]fluorothymidine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Neonatal Congenital Heart Disease
Intervention:
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta
Recruiting - verified March 2012 - Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Schnitzler Syndrome
Intervention:
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified March 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Myelodysplastic Syndromes; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine; Drug: Lenalidomide
Sponsors: Dresden University of Technology; Dresden University of Technology; Celgene Corporation
Recruiting - verified June 2011 - Condition: Hyperandrogenism
Intervention:
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Conditions: Neurofibromatosis Type 1; Malignant Peripheral Nerve Sheath Tumor; Plexiform Neurofibroma; Optic Glioma; Neurofibroma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: May-Hemalin; Fechtner Syndrome (Disorder); Epstein Syndrome (Disorder); MYH9 Related Disorders
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified October 2008 - Conditions: Amatoxin Poisoning; Amanita Poisoning; Mushroom Poisoning; Liver Failure
Intervention: Drug: Legalon SIL (Silibinin)
Sponsors: Madaus Inc; Madaus Inc
Recruiting - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Genetic: loss of heterozygosity analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: tumor replication error analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2010 - Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: molecular genetic technique; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwest Oncology Group
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Other: questionnaire administration; Procedure: digital mammography; Procedure: positron emission mammography
Sponsors: Boston Medical Center; Boston Medical Center; Department of Defense
Recruiting - verified February 2012 - Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Genetic: gene expression analysis; Genetic: molecular genetic technique; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Leukemia
Interventions: Genetic: DNA methylation analysis; Genetic: comparative genomic hybridization; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2007 - Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Traumatic Brain Injury
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - Conditions: Brain Tumors; Central Nervous System Tumors
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin; Drug: vorinostat; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Kidney Transplantation
Interventions: Drug: individual adapted immunosuppression; Drug: golden standard therapy
Sponsors: University Hospital, Ghent; University Hospital, Ghent; Roche Pharma AG
Recruiting - verified December 2011 - Conditions: Colorectal Cancer; Healthy, no Evidence of Disease; Precancerous Condition
Interventions: Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: protein expression analysis; Genetic: proteomic profiling; Other: gas chromatography; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: questionnaire administration
Sponsors: Indiana University; Indiana University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Biotin Deficiency
Interventions: Dietary Supplement: biotin; Dietary Supplement: biotin
Sponsors: University of Arkansas; University of Arkansas; University of Nebraska
Recruiting - verified January 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: Gemtuzumab Ozogamicin (Mylotarg); Drug: standard chemotherapy
Sponsors: University of Ulm; University of Ulm
Recruiting - verified October 2011 - Conditions: Leukemia; Lymphoma; Multiple Myeloma; Plasma Cell Neoplasm; Myelodysplastic Syndromes
Intervention: Biological: human myeloid progenitor cells
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified November 2011 - Condition: IGF1 Deficiency
Intervention: Drug: Increlex®
Sponsors: Ipsen; Ipsen
Recruiting - verified January 2012 - Conditions: Leukemia; Lymphoma
Interventions: Biological: anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Scott and White Hospital & Clinic; National Cancer Institute (NCI)
Recruiting - verified December 2009 - Conditions: Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Intervention: Drug: Lenalidomide
Sponsors: Groupe Francophone des Myelodysplasies; Groupe Francophone des Myelodysplasies; Celgene Corporation
Recruiting - verified February 2010 - Condition: Anesthesia, General
Interventions: Drug: muscle relaxant; Drug: normal saline
Sponsors: Hopital Foch; Hopital Foch
Recruiting - verified January 2012 - Condition: Williams Beuren Syndrome
Interventions: Drug: Minoxidil; Drug: Placebo
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified July 2011 - Condition: Cardiac Arrest
Interventions: Procedure: Therapeutic Hypothermia; Procedure: Therapeutic Normothermia
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011 - Condition: Turner Syndrome
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institute of Mental Health (NIMH)
Recruiting - verified December 2011 - Condition: Cardiac Arrest
Interventions: Procedure: Therapeutic Hypothermia; Other: Therapeutic Normothermia
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011 - Conditions: Neoplasms by Histologic Type; Leukemia, Lymphoid; Leukemia, T-Cell; Solid Tumors
Intervention: Drug: PF-03084014
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Chorioamnionitis
Interventions: Drug: Unasyn; Drug: Ampicillin/gentamicin
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012 - Condition: Schizophrenia
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Recruiting - verified August 2011 - Condition: Bladder Exstrophy
Intervention:
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center
Recruiting - verified June 2011 - Conditions: Cervical Neoplasia; HPV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: treosulfan; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012 - Conditions: Sleep-disordered Breathing; Chronic Heart Failure
Intervention:
Sponsors: LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology; LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
Recruiting - verified June 2011 - Conditions: Non-Hodgkin's Lymphoma; Solid Cancers
Intervention: Drug: GDC-0941
Sponsors: Genentech; Genentech
Recruiting - verified September 2011 - Condition: Solid Cancers
Intervention: Drug: GDC-0941
Sponsors: Genentech; Genentech
Recruiting - verified September 2011 - Conditions: Obstructive Sleep Apnea; Intermittent Hypoxemia
Intervention: Device: Continuous Positive Airway Pressure (CPAP)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; National Institutes of Health (NIH)
Recruiting - verified July 2011 - Conditions: Breast Masses; Breast Cysts
Intervention: Procedure: Breast Ultrasound imaging
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Chronic Myeloproliferative Disorders; Fanconi Anemia; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Osteoarthritis; Traumatic Arthritis; Avascular Necrosis of the Femoral Condyle; Moderate Varus; Valgus; Flexion Deformities
Intervention: Device: NexGen LPS-Flex Mobile Bearing Knee
Sponsors: Zimmer, Inc.; Zimmer, Inc.
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Drug: CEOP regimen; Drug: CHOP regimen
Sponsors: Fudan University; Fudan University
Recruiting - verified February 2012 - Conditions: Stroke; Transient Ischemic Attack
Interventions: Drug: Antithrombotic treatment; Device: percutaneous device closure of PFO
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; University Hospital, Basel, Switzerland; University of Lausanne Hospitals; University Hospital, Geneva; University Hospital, Zürich; Triemli Hospital; Cantonal Hospital of Aarau, Switzerland; Alfried-Krupp Krankenhaus of Essen, Germany; University Hospital, Essen; Klinikum Worms gGmbH, Germany; Tufts Medical Center; Baystate Medical Center; East Medical Center Tyler, Texas; Universitaire Ziekenhuizen Leuven
Recruiting - verified January 2012 - Condition: Non-Hodgkin's Lymphoma, Solid Cancers
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Metabolic Syndrome
Interventions: Dietary Supplement: MUFA MOVE! (Monounsaturated fatty enriched diet); Dietary Supplement: PUFA MOVE! (Polyunsaturated fatty acid enriched diet)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; University of Maryland
Recruiting - verified March 2012 - Conditions: Piebaldism; Idiopathic Anaphylaxis; Allergy; Chronic Urticara; Angioedema
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre
Recruiting - verified March 2012 - Condition: Diabetic Macular Edema
Interventions: Device: Warp 10 LED Device; Device: Near-infrared light (NIR)
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; The New York Eye & Ear Infirmary
Recruiting - verified April 2012 - Conditions: ESRD; Hemodialysis
Intervention: Device: Lifeline
Sponsors: Cytograft Tissue Engineering; Cytograft Tissue Engineering
Recruiting - verified July 2011 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Angina Pectoris; Left Ventricular Wall Motion Abnormalities
Intervention: Procedure: 2D-strain echo
Sponsors: RWTH Aachen University; RWTH Aachen University
Recruiting - verified March 2012 - Condition: Obstructive Sleep Apnea
Intervention: Other: physical exercise program
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble; AGIR à Dom
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Intervention: Procedure: Cardiac MRI
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; National Heart, Lung, and Blood Institute (NHLBI); University of Florida; University of Pittsburgh
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide, Decitabine
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified February 2012 - Condition: Stroke
Interventions: Other: Exercise- Strength Training; Other: Exercise- Stretching Control
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified December 2011 - Conditions: Cleft Palate; Cleft Lip
Intervention:
Sponsors: Region Skane; Region Skane; Karolinska Institutet; Göteborg University
Recruiting - verified August 2011 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: National Cancer Institute (NCI); Asan Medical Center
Recruiting - verified July 2009 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: bortezomib; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Merck; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Carcinoma, Non-small Cell
Intervention: Drug: Dacomitinib (PF-00299804)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Pancreatic Head Mass
Intervention: Procedure: Transgastric diagnostic endoscopic peritoneoscopy
Sponsors: Ohio State University; Jeffrey Hazey; Natural Orifice Surgery Consortium for Assessment and Research
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Aniridia
Intervention: Device: Surgery
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified August 2011 - Condition: Kartagener Syndrome
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Conditions: Polycystic Ovary Syndrome; Obstructive Sleep Apnea; Obesity
Interventions: Drug: Progesterone; Drug: testosterone; Drug: glucocorticoid; Device: continuous positive airway pressure; Drug: Estrogens
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified February 2012 - Condition: Andropause
Intervention: Drug: AndroGel® (testosterone gel)
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Heart, Lung, and Blood Institute (NHLBI); Abbott
Recruiting - verified January 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: fludarabine phosphate; Drug: treosulfan; Radiation: total-body irradiation; Procedure: umbilical cord blood transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Migraine
Intervention: Drug: Clopidogrel
Sponsors: Laval University; Laval University; Sanofi-Aventis; Bristol-Myers Squibb
Recruiting - verified May 2012 - Conditions: Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Peripheral T-cell Lymphoma; Plasma Cell Neoplasm; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Drug: tacrolimus; Radiation: total-body irradiation; Procedure: allogeneic bone marrow transplantation; Biological: natural killer cell therapy; Genetic: fluorescence in situ hybridization; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Patent Ductus Arteriosus
Intervention:
Sponsors: University of Utah; University of Utah
Recruiting - verified December 2011 - Conditions: Primary Ciliary Dyskinesia; Kartagener Syndrome
Intervention: Other: Blood sample
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Condition: Chronic Lung Disease
Intervention: Other: whole blood sample
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Condition: Marfan Syndrome
Interventions: Drug: Losartan; Drug: Placebo
Sponsors: University Hospital, Ghent; University Hospital, Ghent; IWT, Belgium
Recruiting - verified March 2012 - Conditions: CURRARINO Syndrome; Sacrococcygeal Teratoma; Presacral Mass
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011 - Conditions: Congenital Abnormalities; Birth Defects; Congenital Defects
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified May 2012 - Conditions: Pulmonary Embolism; Deep Vein Thrombosis
Intervention: Other: Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.
Sponsors: University Hospital, Geneva; University Hospital, Geneva; Swiss National Science Foundation
Recruiting - verified October 2008 - Condition: Severe Congenital Diaphragmatic Hernia
Intervention: Device: Percutaneous endoscopic fetal tracheal occlusion/unocclusion
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Conditions: WAGR Syndrome; Wilm's Tumor; Aniridia; Urogenital Abnormalities; Mental Retardation
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Condition: Marfan Syndrome
Interventions: Drug: placebo; Drug: Losartan
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2008 - Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)Conditions: Chronic Lymphocytic Leukemia; Leukemia
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Congenital Heart Disease
Intervention:
Sponsors: Emory University; Emory University
Recruiting - verified June 2011 - Condition: Pyelonephritis
Interventions: Drug: Trimethoprim Sulfamethoxazole; Drug: placebo
Sponsors: University of Alberta; University of Alberta; Canadian Urological Association
Recruiting - verified September 2011 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Hypoparathyroidism; Hypocalcemia
Intervention: Drug: Synthetic Human Parathyroid Hormone 1-34
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Condition: Heart Disease
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Medical University of South Carolina
Recruiting - verified March 2012 - Conditions: Wound Healing; Abdominal Surgery
Intervention:
Sponsors: Klinikum St. Georg gGmbH; Klinikum St. Georg gGmbH; Martin-Luther-Universität Halle-Wittenberg
Recruiting - verified December 2011 - Conditions: Diabetes Mellitus; Healthy Volunteers
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011 - Conditions: Stroke; Transient Ischemic Attack
Intervention: Device: GORE HELEX™ Septal Occluder
Sponsors: W.L.Gore & Associates; W.L.Gore & Associates
Recruiting - verified September 2011 - Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: digital mammography
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011 - Condition: Major Depressive Disorder
Interventions: Dietary Supplement: Creatine monohydrate; Dietary Supplement: Placebo
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified March 2012 - Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: Computer aided analysis of breast lesions
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified August 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Childhood Anaplastic Large Cell Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Chronic Lymphocytic Leukemia; Refractory Cytopenia With Multilineage Dysplasia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Breast Abnormalities; Breast Masses
Intervention: Procedure: Tomosynthesis and ultrasound imaging
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Condition: Patent Ductus Arteriosus
Interventions: Other: feeding; Other: fasting
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Brain Concussion
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Procedure: umbilical cord blood transplantation; Drug: cyclosporine; Procedure: double-unit umbilical cord blood transplantation; Other: laboratory biomarker analysis; Procedure: biopsy; Other: immunologic technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Congenital Heart Disease
Intervention:
Sponsors: Columbia University; Columbia University
Recruiting - verified December 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Orlistat (Alli) and Lifestyle Intervention with exercise and diet; Drug: Loestrin 1/20; Drug: Orlistat (Alli) and Loestrin 1/20
Sponsors: Penn State University; Penn State University; University of Pennsylvania
Recruiting - verified November 2011 - Conditions: Pompe Disease; Glycogen Storage Disease Type II (GSD-II); Glycogenesis 2 Acid Maltase Deficiency
Interventions: Biological: Myozyme (alglucosidase alfa); Biological: Myozyme (alglucosidase alfa)
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2012 - Conditions: Focal Dermal Hypoplasia (FDH); Goltz Syndrome; X Linked Disorders
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH); National Foundation for Ectodermal Dysplasias; March of Dimes
Recruiting - verified June 2011 - Condition: Marfan Syndrome
Interventions: Drug: Losartan and nebivolol; Drug: Losartan; Drug: Nebivolol
Sponsors: IRCCS Policlinico S. Matteo; IRCCS Policlinico S. Matteo; Merck; Menarini Group
Recruiting - verified July 2011 - Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Conditions: Aging; Insulin Resistance
Interventions: Drug: Testosterone; Drug: Estrogen
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Conditions: Congestive Heart Failure; Arrhythmias
Intervention: Other: Congestive heart failure
Sponsors: Columbia University; Columbia University; Medtronic
Recruiting - verified February 2012 - Conditions: Primary; Complex; Pigmented Nodular Adrenocortical Disease, Primary, 1; Periorificial Lentiginosis; Cardiac Myxoma
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified December 2011 - Condition: Abnormalities, Radiation-Induced
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Carol M. Baldwin Breast Cancer Research Fund, Inc.
Recruiting - verified July 2011 - Condition: Brain Disorders
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2011 - Condition: Atrial Septal Defect
Intervention: Device: AMPLATZER Septal Occluder
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified May 2010 - Condition: Ventricular Septal Defects
Intervention: Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified October 2009 - Condition: Pregnant Women
Interventions: Drug: Clindamycin; Drug: Placebo; Drug: Clindamycin
Sponsors: University Hospital, Lille; University Hospital, Lille; Pfizer
Recruiting - verified January 2008 - Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Mesothelioma
Interventions: Drug: N-Acetylcysteine; Drug: Placebo
Sponsors: Rijnstate Hospital; Rijnstate Hospital
Recruiting - verified August 2011 - Condition: Solid Tumors
Intervention: Biological: MT110
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Biological: sargramostim; Drug: busulfan; Drug: cyclophosphamide; Drug: dexamethasone; Drug: etoposide; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation; Procedure: Bone marrow aspiration and biopsy; Procedure: Apheresis
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Conditions: Anencephaly; Spina Bifida; Neural Tube Defect
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified June 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009 - Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia; Procedure: Normothermic Control
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified September 2011 - Conditions: Unexplained Isolated Provoked Hemorrhages; Familial Bleeding Disorder; Scott Syndrome
Intervention: Other: Blood withdrawal
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France; Louis Pasteur University, Strasbourg; Institut National de la Santé Et de la Recherche Médicale, France; Aventis, Génopôle d'Evry.
Recruiting - verified November 2011 - Conditions: Tachycardia; Postural Orthostatic Tachycardia Syndrome
Interventions: Radiation: DAXOR; Procedure: QSweat; Drug: Intrinsic Heart Rate
Sponsors: Vanderbilt University; Satish R. Raj; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Respiratory Insufficiency
Interventions: Other: Nasal CPAP; Other: Humidified High Flow Nasal Cannula (HHFNC)
Sponsors: University of Utah; University of Utah; Intermountain Health Care, Inc.
Recruiting - verified April 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Radiation: iodine I 131 monoclonal antibody BC8; Procedure: allogeneic bone marrow transplantation; Drug: tacrolimus; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Birth Defects; Type 2 Diabetes; Preterm Birth
Intervention:
Sponsors: INC Research; INC Research; Amylin Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Multifocal Lymphangioendotheliomatosis With Thrombocytopenia; Cutaneovisceral Angiomatosis With Thrombocytopenia; Vascular Anomaly With Thrombocytopenia; Hemangiomas
Intervention: Other: no intervention
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin
Recruiting - verified November 2011 - Condition: Pancreatic Cancer
Intervention:
Sponsors: University of Alabama at Birmingham; Charles Mel Wilcox, MD; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Barrett's Esophagus; High Grade Dysplasia
Interventions: Procedure: Photodynamic therapy; Procedure: radiofrequency ablation of barrett's esophagus
Sponsors: Mayo Clinic; Mayo Clinic; National Institutes of Health (NIH)
Recruiting - verified March 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: ABT-888; Drug: topotecan hydrochloride; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Neoplasm; Arteriovenous Malformations
Intervention: Radiation: Radiosurgery
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Health Services Foundation; The Kirklin Clinic at Acton Road
Recruiting - verified July 2011 - Conditions: Patent Foramen Ovale; Stroke
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Available - verified September 2011 - Conditions: Chronic Fatigue Syndrome; Orthostatic Intolerance; Postural Tachycardia Syndrome
Interventions: Other: Autonomic Function Testing; Other: Saline infusions; Drug: L-NMMA trimethaphan; Drug: methyldopa
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Heart Disease
Intervention: Procedure: noninvasive tests
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified March 2012 - Condition: Healthy
Intervention: Other: Cardiac MRI
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified March 2012 - Conditions: Liver Diseases; Alagille Syndrome; Alpha 1-Antitrypsin Deficiency
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Condition: Sickle Cell Disease
Interventions: Other: NO-CO inhalation and expiration; Other: NO-CO inhalation and expiration
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified November 2007 - Condition: Testicular Germ Cell Tumor
Interventions: Other: biomarker analysis; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified October 2007 - Conditions: Epilepsy; Localization-related Epilepsy; Infantile Spasms; Lennox-Gastaut Syndrome; Polymicrogyria; Periventricular Heterotopias
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Condition: Congenital Heart Disease
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Recruiting - verified February 2012 - Conditions: Lymphangioleiomyomas; Tuberous Sclerosis; Lymphangioleiomyomatosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: intensity-modulated radiation therapy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Heart Defects, Congenital
Interventions: Drug: nesiritide; Drug: milrinone; Drug: placebo
Sponsors: Children's Hospital Boston; Children's Hospital Boston; American Heart Association
Recruiting - verified June 2011 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Intervention: Biological: donor lymphocytes
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Conditions: Andersen-Tawil Syndrome; Andersen Syndrome
Intervention:
Sponsors: University of Rochester; University of Rochester; Office of Rare Diseases (ORD); Rare Diseases Clinical Research Network; National Center for Research Resources (NCRR)
Recruiting - verified January 2012 - Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Obesity; Metabolic Syndrome
Intervention: Drug: olanzapine and melatonin
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; Eli Lilly and Company
Recruiting - verified November 2011 - Conditions: Breech Presentation; External Cephalic Version; Thyroid Hormones; Stress, Psychological; Congenital Hip Dysplasia
Intervention:
Sponsors: Catharina Ziekenhuis Eindhoven; Catharina Ziekenhuis Eindhoven; University of Tilburg
Recruiting - verified October 2011 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: etoposide; Drug: methotrexate; Drug: rasburicase; Drug: sirolimus; Drug: tacrolimus; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital
Recruiting - verified April 2008 - Condition: Cancer
Interventions: Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Milton S. Hershey Medical Center
Recruiting - verified October 2007 - Conditions: Hypopituitarism; Hypogonadism; Thyroid Dysfunction; Bone Diseases, Metabolic
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Conditions: Wilms' Tumor; Aniridia
Interventions: Behavioral: Questionnaire; Other: Blood specimen
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Obesity
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Dyskeratosis Congenita; Fanconi Anemia; Myelodysplastic Syndromes; Nonmalignant Neoplasm; Pearson Marrow-pancreas Syndrome; Shwachman-diamond Syndrome
Interventions: Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunologic technique; Procedure: biopsy
Sponsors: University Hospital Freiburg; University Hospital Freiburg
Recruiting - verified December 2011 - Conditions: Hypogonadism; Kallmann Syndrome; Puberty, Delayed; Puberty, Precocious; Hypothalamic Amenorrhea; Anosmia; GnRH Deficiency
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Schistosomiasis [Bilharziasis]
Interventions: Drug: Praziquantel; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Conditions: Dystonia; Focal Dystonia; Cerebellar Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Condition: Healthy
Intervention:
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; University of Cincinnati
Recruiting - verified February 2012 - Conditions: Congenital Heart Disease; Atherosclerosis; Myocardial Ischemia; Myocardial Infarction; Acquired Heart Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Alport Syndrome
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified May 2011 - Conditions: Pentalogy of Cantrell; Mutations in Non-muscle Genes
Intervention:
Sponsors: Children's Healthcare of Atlanta; Children's Healthcare of Atlanta; Emory University; University of Texas Southwestern Medical Center; University of California, San Francisco; Ben-Gurion University of the Negev; Brigham and Women's Hospital; Children's Hospital Medical Center, Cincinnati; Children's Hospital and Health System Foundation, Wisconsin; University of Puerto Rico
Recruiting - verified April 2012 - Condition: Clubfoot
Intervention:
Sponsors: University of British Columbia; University of British Columbia; National Institutes of Health (NIH); Shriners Hospitals for Children
Recruiting - verified October 2011 - Condition: Clubfoot
Intervention: Drug: Botulinum Toxin (Type A) injection (10 U/Kg)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified October 2011 - Conditions: Turner Syndrome; Ovarian Failure, Premature; Sex Chromosome Aberrations; Menopause; Perimenopause
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified October 2009 - Conditions: Mycobacterium Infections, Atypical; Granulomatous Disease, Chronic; Job's Syndrome; Influenza, Human
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: Hemangioma, Vascular Anomalies
Interventions: Genetic: Cheek cell samples or blood sample (4mL); Genetic: Cheek cell sample or blood sample (4mL)
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Recruiting - verified April 2012 - Conditions: Graft Versus Host Disease; Infection; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); St. Bartholomew's Hospital
Recruiting - verified September 2007 - Conditions: Amenorrhea; Hypogonadotropic Hypogonadism; Kallmann's Syndrome
Intervention: Procedure: Frequent baseline blood sampling
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Acute Myeloid Leukemia in Remission; Childhood Myelodysplastic Syndromes; de Novo Myelodysplastic Syndromes; Fanconi Anemia; Previously Treated Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Procedure: allogeneic bone marrow transplantation; Drug: mycophenolate mofetil; Drug: cyclosporine; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Drug: arsenic trioxide; Drug: azacitidine; Drug: busulfan; Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: fludarabine phosphate; Drug: gemtuzumab ozogamicin; Drug: melphalan; Drug: tipifarnib; Genetic: DNA methylation analysis; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); The University of New South Wales
Recruiting - verified August 2008 - Conditions: Dyskeratosis Congenita; Aplastic Anemia
Interventions: Drug: Campath 1H; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Total Body Irradiation; Procedure: Stem Cell Transplantation; Drug: ATG
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Hyperparathyroidism; Hypertension
Intervention: Procedure: parathyroidectomy
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified September 2011 - Condition: Congenital Heart Defects
Intervention: Device: implantation and testing of CRT
Sponsors: Competence Network for Congenital Heart Defects; Competence Network for Congenital Heart Defects
Recruiting - verified August 2011 - Conditions: Cardiopulmonary Bypass; Heart Defects, Congenital; Hyperglycemia
Interventions: Drug: Insulin; Other: Usual Care
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009 - Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis
Interventions: Drug: Busulfan; Drug: Cytarabine; Drug: Fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Obesity
Interventions: Procedure: biopsy of muscle, of liver, and of adipose tissue; Procedure: clamp euglycemic - hyperglycemic; Behavioral: diet; Other: biopsies for biological and genetic analyses
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified November 2011 - Conditions: Depressive Disorder, Major; Bipolar Disorder; Panic Disorder; Stress Disorders, Post-Traumatic
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified October 2011 - Conditions: Sleep Apnea, Obstructive; Respiration Disorders
Interventions: Procedure: supraglottoplasty with laser; Procedure: laser supraglottoplasty
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified March 2012 - Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011 - Conditions: Vasculopathy; Allograft
Intervention: Procedure: Dobutamine stress echocardiography, coronarography, brachial arterial echography
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified November 2011 - Conditions: Hypogonadotropic Hypogonadism; Amenorrhea; Kallmann's Syndrome
Interventions: Drug: synthetic gonadotropin releasing hormone (GnRH); Device: Mini-infusion pump
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Condition: Fragile X Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified January 2012 - Condition: Dyslipidemias
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2012 - Conditions: Migraine Headaches; Patent Foramen Ovale
Interventions: Other: Sham Procedure; Device: AMPLATZER PFO Occluder
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention: Procedure: EEG
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France; Institut National de la Santé Et de la Recherche Médicale, France; France: Centre National de la Recherche Scientifique; Faculté de Médecine de Strasbourg
Recruiting - verified November 2011 - Conditions: Birth Defects; Pregnancy Complications; Epilepsy; Seizures
Intervention:
Sponsors: INC Research; INC Research; UCB, Inc.
Recruiting - verified March 2012 - Condition: Klinefelter Syndrome
Interventions: Drug: androgen oxandrolone; Other: placebo
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified July 2011 - Conditions: Congenital Anomalies; Imaging; Prenatal Care
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: ex-vivo umbilical cord blood expansion; Procedure: double-unit umbilical cord blood transplantation; Procedure: biopsy; Other: immunologic technique; Other: diagnostic laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Fetal Growth Abnormalities
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011 - Condition: Neimann-Pick Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2011 - Condition: Preterm Birth
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2011 - Condition: Hereditary Oral Clefts
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2011 - Conditions: Preterm Labor; Infant Neurological Disorders
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011 - Conditions: Pseudoxanthoma Elasticum; PXE
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Glioma
Interventions: Procedure: MRS Imaging; Procedure: PET Scanning; Procedure: Diffusion Tensor Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Conditions: Kartagener Syndrome; Cystic Fibrosis; Pseudohypoaldosteronism; Primary Ciliary Dyskinesia
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Rare Diseases Clinical Research Network; National Center for Research Resources (NCRR); NIH Office of the Director
Recruiting - verified February 2012 - Conditions: Flail Chest; Ventilation
Intervention: Procedure: operative fixation of fractured ribs
Sponsors: The Alfred; The Alfred
Recruiting - verified February 2012 - Condition: Ischemia
Intervention:
Sponsors: University of South Alabama; University of South Alabama; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2011 - Conditions: Glioma Tumor Recurrence; Radiation Necrosis; Primary Brain Tumor
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Sertraline (drug)
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Procedure: Biopsy of the major carinal area; Procedure: Biopsy of abnormal & suspicious areas of the bronchial tree; Procedure: Evaluation of the tumor for DNA mutations; Procedure: Bronchoalveolar Lavage (BAL) for cytokine analysis; Procedure: Correlation of flow cytometric & RT PCR for TNM stage; Procedure: Analysis of lymph nodes
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Conditions: Hyper-IgM Syndrome; Ectodermal Dysplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Turner Syndrome
Intervention: Drug: Somatropin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Mevalonic Aciduria; Mevalonate Kinase Deficiency; Immune System Diseases; Periodic Fever Syndromes, Hereditary; Lipid Metabolism, Inborn Errors
Intervention:
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified March 2012 - Conditions: Excess Androgen; Congenital Adrenal Hyperplasia (CAH); Familial Male-Limited Precocious Puberty (FMPP)
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Conditions: Lymphocyte Homeostasis; Genetic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Glanzmann Thrombasthenia
Intervention:
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified January 2012 - Condition: Clubfoot
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified October 2011 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Ischemia
Intervention:
Sponsors: Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Condition: Ischemia
Intervention:
Sponsors: Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Conditions: Systemic Lupus Erythematosus; Antiphospholipid Syndrome
Intervention:
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified December 2011 - Condition: Diabetes Mellitus
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; Michael Mauer, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
Recruiting - verified July 2011 - Condition: Immune System Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Urinary Incontinence
Interventions: Procedure: Surgery; Procedure: Medical Treatment
Sponsors: University of British Columbia; University of British Columbia; Vancouver Foundation
Recruiting - verified February 2012 - Conditions: Chagas Disease; Trypanosomiasis; Heart Disease
Interventions: Drug: Benznidazole; Drug: Placebo
Sponsors: Population Health Research Institute; Population Health Research Institute; Canadian Institutes of Health Research (CIHR); World Health Organization; Dante Pazzanese Institute; Hospital das Clinicas de Ribeirao Preto/USP
Recruiting - verified June 2005 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Birth Defects; Pregnancy Complications; Hepatitis C
Intervention:
Sponsors: INC Research; INC Research; Aurobindo; Genentech; Sandoz Inc.; Merck; Teva Pharmaceuticals USA; Kadmon Pharmaceuticals, LLC; Zydus Pharmaceuticals USA, Inc.
Recruiting - verified October 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; HIV Infection; HIV-associated Hodgkin Lymphoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified November 2011 - Conditions: Craniosynostosis; Muenke Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011 - Conditions: Retinitis Pigmentosa Syndromic; Congenital Deafness; Usher Syndrome; Retinitis Pigmentosa and Deafness; Progressive Hearing Loss; Retinitis Pigmentosa
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified July 2011 - Condition: Tomography, Emission-Computed
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified April 2012 - Conditions: Hemoglobinopathies; Hemolysis; Iron Deficiency and Overload; Anemias
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011 - Conditions: Solid Tumors; Lymphomas
Interventions: Drug: etoposide; Drug: Oxaliplatin; Drug: Ifosfamide
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Eosinophilia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: bone marrow aspiration; Procedure: peripheral blood stem cell transplantation; Genetic: polymerase chain reaction; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011 - Condition: Holoprosencephaly
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2011 - Condition: Spondylitis, Ankylosing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Conditions: Inborn Genetic Diseases; Pentalogy of Cantrell
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Condition: Bardet-Biedl Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2011 - Conditions: Nervous System Malformations; Arthropathy, Neurogenic; Urticaria; Papilledema
Intervention: Drug: Anakinra
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified November 2011 - Conditions: Autosomal Recessive Polycystic Kidney Disease; Congenital Hepatic Fibrosis; Caroli's Disease; Polycystic Kidney Disease; Joubert Syndrome; Cerebro-Oculo-Renal Syndromes; COACH Syndrome; Senior-Loken Syndrome; Dekaban-Arima Syndrome; Cogan Oculomotor Apraxia; Nephronophthisis; Bardet-Biedl Syndrome; Alstrom Syndrome; Oral-Facial-Digital Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Brain Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Neurologic Disorders
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified January 2012 - Conditions: Urticaria; Arthropathy; Lymphadenopathy; Nervous System Anomalies
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Conditions: Healthy; Pituitary Disease; Thyroid Disease
Intervention: Drug: TRH (Thyrotropin Releasing Hormone)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012 - Condition: Ovarian Cancer
Interventions: Genetic: comparative genomic hybridization; Genetic: cytogenetic analysis; Genetic: gene rearrangement analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2007 - Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Lipoidosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Conditions: Epilepsy; Seizures; Cognition Disorders; Neuronal Migration Disorders
Intervention:
Sponsors: Harvard University Faculty of Medicine; Harvard University Faculty of Medicine; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified July 2011 - Conditions: Complex Regional Pain Syndromes; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Nursing Research (NINR)
Recruiting - verified February 2012 - Condition: Glioma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Dystonia; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Conditions: Rheumatic Diseases; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Conditions: Breast Neoplasms; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Fanconi's Anemia; Anemia, Diamond Blackfan; Dyskeratosis Congenital; Thrombocytopenia; Neutropenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Genetic Disorder; Metabolic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Condition: Lipodystrophy
Intervention: Drug: Metreleptin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: Parkinson's Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified June 2011 - Condition: Rheumatic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011 - Conditions: Sensorineural Hearing Loss; Cytomegalovirus Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified December 2011 - Conditions: Atypical Mycobacterium Infections; Cystic Fibrosis; Job's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Common Variable Immunodeficiency
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Conditions: Chromosome Abnormalities; Smith Magenis Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011 - Conditions: Healthy; Sickle Cell Anemia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Conditions: Adult Langerhans Cell Histiocytosis; Childhood Langerhans Cell Histiocytosis; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2007 - Condition: Turner's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Immunologic Deficiency Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2011 - Condition: Chediak Higashi Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012 - Conditions: Syringomyelia; Type I Arnold Chiari Malformation
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified December 2011 - Conditions: Bipolar Disorder; Healthy; Mood Disorder; Parkinson's Disease; Schizophrenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified September 2011 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: Glomerulonephritis; Lupus Nephritis; Membranous Glomerulonephritis; Nephritis; Nephrotic Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011 - Conditions: Hereditary Neoplastic Syndrome; Tuberous Sclerosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI); United States Uniformed Health Service
Recruiting - verified April 2012 - Conditions: Malformations; Multiple Abnormalies; Polydactyly
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified April 2012 - Conditions: Cockayne Syndrome; Skin Neoplasm; Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Abnormalities; Inborn Errors of Metabolism; Mental Retardation; Muscle Hypotonia; Smith Lemli Opitz Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2010 - Conditions: Abnormalities; Craniopharyngioma; Cushing's Syndrome; Endocrine Disease; Pituitary Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Conditions: Growth Disorder; Mental Retardation; Multiple Abnormalies
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012 - Conditions: Dwarfism; Osteogenesis Imperfecta
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Condition: Lung Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Hypercalcemia; Hyperparathyroidism; Multiple Endocrine Neoplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011 - Conditions: Autoimmune Disease; Lymphatic Disease; Lymphoproliferative Disorder; Canale-Smith Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Conditions: Healthy; Schizophrenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified October 2011 - Conditions: Communicable Disease; Immunologic Deficiency Syndrome; Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Albinism; Intestinal Disease; Kidney Disease; Myocardial Disease; Pulmonary Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2011 - Condition: Stuttering
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified October 2011 - Conditions: Healthy; Immunologic Deficiency Syndrome; Job's Syndrome; Severe Combined Immunodeficiency
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: HIV Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); Washington Hospital Center
Recruiting - verified January 2012 - Conditions: Chronic Granulomatous Disease; Healthy; Immunologic Disease; Leukocyte Adhesion Deficiency Syndrome; Severe Combined Immunodeficiency
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 2011 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified December 2011 - Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Conditions: Lung Disease; Pneumothorax; Tuberous Sclerosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Conditions: Cystic Fibrosis; Sarcoidosis; Tuberous Sclerosis; Asthma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Conditions: Autoimmune Disease; Congenital Adrenal Hyperplasia; Healthy; Mental Disorder Diagnosed in Childhood; Neurologic Manifestations
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified September 2011
 |
Join Clinical trials for Congenital Anomalies |
